b e h r n g e r n g e l h e value partnershipc n e n trust patient able rely receive good possible therapy medicine enquire life partnership important successfully regain confidence boehringer ingelheim body stroke progress space partnership play major role boehringer balance security space ingelheim research development good basis good idea benefit patient open idea power people innovation call strong scientific partner hr manager discuss limit indi viduality diversity explore new horizon strong research development cooperation contribute success work combat counterfeit pharmaceutical company counterfeit medicine success tradition space special corporate culture imprint learn science fiction look future medication longterm partnership benefit patient pharmaceutical company payer organisation work long term partner passion animal health boehringer ingelheim new animal health business look likevalue h r u g h p r n e r h p today researchdriven pharmaceutical company boehringer ingelheim focus variety partnership intensive networking company important exchange cooperation external partner boehringer ingelheim world lead pharmaceutical company headquarter ingelheim germany boehringer ingelheim operate globally currently total employee focus familyowned company found research develop manufacturing market e new medication high therapeutic benefit people animal embrace social responsibility important element boehringer ingelheim corporate culture include worldwide commitment social project make health initiative pay close attention employee respect equal opportunity reconcile career private life form founda tion togetherness company focus environmental protection sustainability boehringer ingelheim achieve net sale billion euro rd expenditure correspond cent net sale enquire w h p r n e r h p r e p r n f r b e h r n g e r n g e l h e boehringer ingelheim today partnership important ask chairman shareholder committee member board manage director value partnership company contribute success enquire establishment scien tific department cooperation heinrich wieland cooperation pfizer novo geigy aim build international business important historic example partnership partnership continue play sig nificant role future effort offer customer measurable affordable act therapeutic progress purely innovative medicine innovative company act find solution time remain independent family find own company solution christian boehringer chairman shareholder committee enquire n animal health business partnership vital success key dimension supply additional service improve customer order provide value product rd ability work external partner develop innovative tech nologie research approach innovate idea product solution indepth possible diverse team com compete bin different skill capability stand worldwide build global hub intensify cooperation hubertus von baumbach customer animal health strategy chairman board manage director vastly accelerate inte gration merial need allan hillgrove p member board managing artnering help develop director responsibility strengthen capability human pharma serve customer well innovative partner allow improve ability innovate ability technology compete look partnership central horizon partner decisive build future success boehringer e strong relation customer research ingelheim partnership well understanding need require firstly indepth allow improve result approach understand customer need bring health patient meeting need mutually beneficial way future partner dr joachim hasenmaier ship likely include cooperate member board manage payer reimbursement body director responsibility define value product animal health society pay delivery value partnership involve gain expertise outside company employ competitive responsive enquire p artnership key success company think partnership think partnership internally externally level outside organi sation think partnership achieve customer patient stakeholder employee work collaborate foster inclusive optimise culture drive diverse thinking innovation organisation result true partnership team strive partner goal team way say simone menne choice achieve member board manage director responsibility external finance p artnership mean support drive innovator share knowledge combine strength diverse dr michel pairet finance division member board manage apply external partner think director responsibility internal business partner innovation particular innovation overcome challenge major project p achieve optimise result artnership key inno dr andreas neumann vation discovery member board managing individual act director responsibility usually begin human resource single person idea test experimentally discussion exchange creative mind internally externally develop true solution aspiration boehringer ingelheim partner choice external innovator establish creative cooperative environment bring scientist diverse ground key ambition breakthrough innovation value patient family society p r g r e h r u g h p r n e r h p boehringer ingelheim researchdriven pharmaceutical company progress essential sustained success partnership play increasingly important role external researcher health insurer patient progress boehringer ingelheim foremost mean help people animal innovative medicine worldwide p r g r e h r u g h p r n e r h p progress partnership p e n e develop new medicine call power innovate strong scientific partner boehringer ingelheim new research strategy back open innovation interaction external specialist inspire research openness mean recruit outstanding scientist progress partnership dr clive r wood open innovation good sense boehringer ingelheim understand look medicine future say wood corporate senior vice open good new idea president human pharma concept inspire research discovery research development work boehringer emerge head eye ingelheim open precisely innovation happen internally exter nally way building reverse ideal cradle innovation core cause disease expert weill cornell hand contribute profound understanding chronic pulmonary disease extensive experience lung research team line boehringer ingelheim hand particular expertise new research come discover develop new respiratory therapy complement hortness breath perfectly excellent field emerge persistent cough combination enable rapidly usually translate new scientific finding sign chronic pharmaceutical research develop obstructive pulmonary disease copd ment say dr clive r wood boehringer ingelheim truly widespread disease great corporate senior vice president disco reshape discovery research strategy number people age research wood essentially research new medicine affect high risk estimate company head research divide research area million people worldwide suffer human pharma immunology respiratory disease disease prevalent scientist academic cardiometabolic disease oncology diabetes expert estimate research company share disease central nervous system fatality attribut passion new discovery work ability modulate bodys able copd disease incurable translate new immune system open new exciting treatment improve medicine say wood explain way treat cancer consequently symptom counter partnership like promise discovery research organisation dangerous downward spiral increase researcher grow stud boehringer ingelheim plan ailment physical inactivity ie uk spend majority increase investment oncology help patient researcher career usa work additional research therapeutic boehringer ingelheim weill cornell ing boehringer ingelheim headquar area focus immunooncology department genetic medicine ter ingelheim germany boehringer ingelheim estab usa break completely new line new lishe overarch scientific platform ground conduct research field emerge constantly immune modulation focus research deterioration engage intensive interaction expertise resource area cut small airway stop external expert multiple therapeutic area progress partnership biberach germany ridgefield ct usa vienna austria kobe japan boehringer ingelheim major global research development site human pharmaceutical research border ofthe art capability protein bio possible company company establish pro therapeutic deliver researcher publish gramme explore emerge scientific onequarter new candidate scientific article prestigious approach technology collab early pipeline say wood journal wood proud large oration external partner number believe key perfor core research mance indicator innovation therapeutic area important recruit boehringer ingelheim commit generation talente scientist time right develop generation company today good young pioneer medicine goal mind attract publication improve live patient high journal find place medical need new insight great science bring new medi pathway drive disease critically fully involved cine patient important identify breakthrough research border serve medicine future say wood radar big wave innovation creativity commitment open innovation require active collaborate external research insight centrally important twoway communication external institution boehringer ingelheim drughunte spirit world explain whilst ensure scientist new drug target ensure appropriate protection finger pulse miss identify researcher decide good innovation enormous new research method approach therapeutic purpose work share emerge connect history develop wood believe external engage good partner longterm partnership exceptional ability discover ment participation great university kyoto univer develop small molecule drug scientific community essential create sity japan harvard contribute lead pipeline expand connection facilitate heart research success sure continue path future opportunity border critical core driver future convince scientific publication boehringer ingelheim active success large molecule drug crucial communication public private partnership require address significant researcher encourage col structural genomics consortium range therapeutic target league boehringer ingelheim seek solution difficult recent year develop state publish finding medical problem crowdsource progress partnership project way boehringer ingelheim eye topic early research development conceptual stage wood continue time right ready fully involve immune modulation example scientific platform approach boehringer ingelheim immune system common denominator boehringer ingelheim com disease wide variety mitte research development medical area wood explain previ ously company employ immunologist relevant therapeutic area team ve bring single unit instead specialist sational unit immune modulation carry research identify novel underlie mechanism drive possibility influence immune billion euro fibrosis example scientific platform system immune pathway research development approach boehringer ingelheim expenditure turn disease auto currently explore wood immunity excessive colleague discuss activation immune system ing area regenerative medi pathway cine possibility turn fight cancer new culture openness insufficient activation mutually beneficial partnership immune system create enormous research guide company value scientist work people research development wood state common problem work research mention ofev outstanding oppose work different organi development example company medicine make strong contribution sale growth tyrosine kinase inhibitor nintedanib boehringer ingelheim oncology research division originally develop highly effective lung cancer medicine talented scientist biberach site germany hit idea mechanism drive cancer effective idiopathic lung fibrosis say course imply active ingredient nintedanib treat disease demon strate potential series experiment successfully argue test nintedanib additional indication importance common disease mechanism show important open mind ambition help patient heart drug discovery boehringer ingelheim reshape discovery research strategy progress partnership e x p l r n g n e w h r z n g e h e r w e r e r n g e r transform bright scientific idea new medicine patient need require stay powerand increasingly strong international network partner boehringer ingelheim continually seek strong partner world pursue new path drug discovery progress partnership oncolytic virus promise therapeutic crossing boundary approach cancer research boehringer ingelheim launch new strategy global research organisa innovation partnership tion combine focus company boston strength increase use internal synergy bold commitment external boehringer ingelheim office boston innovation research border usa goal expand network initiative represent new approach scientist organisation example aim explore novel scientific approach boehringer ingelheim work scien innovative technology tist harvard stem cell institute boehringer ingelheim core therapeutic area fibrosis network order study new treat future focus area company ment option fibrotic disease life science research asia rapidly fibrosis characterise patholog grow importance offer significant ical proliferation fibrous connective tissue new opportunity pharmaceutical discov organ boehringer ingelheim ery research particular area focus harvard university scientist carry regenerative medicine area collaboration research disease idiopathic pul excellence threeyear partnership combat cancer monary fibrosis chronic kidney failure kyoto university japan way nonalcoholic steatohepatitis look scientist boehringer ingelheim goal boehringer ingelheim cancer pathophysiological mechanism kyoto university investigate novel thera research develop new therapy imp rove root fibrosis prove peutic approach restore hearing ability patient live achieve company gamechange treat fibrotic disease people disable hearing loss continue expand network partner advantage partnership million people live severe condi ship academic institution biotech researcher able pursue tion million child nology company relationship focus work great depth worldwide age population dramatic early emerge science technology leverage synergy share resource increase frequency condition aim true breakthrough therapy efficiently expect hear loss increase age need patient caregiver effective treatment healthcare system requirement guide restore hear loss sufferer rely researcher hear aid example strategic partner joint research team pursue new ship viratherapeutic biotech com hair cell inner ear idea aim understand mechanism pany locate innsbruck austria regeneration damage hair cell investigate virusbase immunotherapeu inner ear hearingimpaired people tic cancer treatment april sensory cell long work properly boehringer ingelheim venture fund new therapeutic approach intend lead investor viratherapeutic restore overcome limitation oncolytic virus prom hearing aid ise emer ge therapeutic approach boehringer ingelheim open office cancer research company september kyoto universitys med pursue earlystage research examine ical innovation center establish col cancerdestroye oncolytic virus laboration scientist japan september broaden boehringer ingelheim oncolytic virus act infect research field hear loss destroy cancer cell process lead research border team recently release tumor antigen launch partnership china normally hide immune system southeast university nanjing bodys cell socalle situ vaccina focus complementary approach tion effect trigger sustain response restore hearing ability adaptive immune system tumour cell pprrooggrreessss tthhrroouugghh ppaarrttnneerrsshhiipp guest contribution l e r n n g f r c e n c e basis different trend identify highly likely reality year f c n trend self aware patient patient selfimage evolve healthcare set undergo revolutionary change undergo year time pill produce printer radical transformation everyday life like virtualreality application hospital patient selfaware crit ical doctor pharmaceutical healthcare company prepare new era manufacturer tell patient partner intent inform prophylactically disease diagnose possible treat ment internet enable patient achieve level knowledge approach doctor invest time patient future insist play nyone interested sight healthcare sector active role decide hap future hold read science face era change real tsuna mi pen company fiction story watch science approach impact healthcare sector doctor fiction film future feel year different mean adapt fact patient turn like star trek example idea severe demand treat partner movie ex machina story serve change today paralyse valuable source inspiration people able walk thank trend science fiction glue bind exoskeleton printer enable victory parade today tomorrow help customfit cast splint individual sensor exponential thinking need patient plan drone meaningful assumption deliver defibrillator emergency sensor measure assess future likely bring linear think patient doctor unable vital function people e simply extrapolate current time spread rapidly year development future consider science fiction year socalle electronic tattoo forward evident ago today reality available market continu glance industry inspire ously measure body temperature undergo radical change science fiction familiar current pulse rate blood pressure past year trend healthcare information son skin tattoo attach internet retail medium technology think exponentially sensor soon instal bath pprrooggrreessss tthhrroouugghh ppaarrttnneerrsshhiipp room people home trend instance analyse people urine augmented day offer new opportunity virtual reality health insurer example people follow healthconscious lifestyle offer discount augment reality increase number people seek bodys lip month optimise health pokmon smartphone game example record number future everyday occurrence deep sleep period healthcare industry night adjust daytime behaviour possible application augman achieve well recovery bertalan mesk ted reality enable doctor partici nighttime pate operation perform md phd remotely datum glass enable significantly effective sha trend red training junior medic print possible past virtual dissect room opera cancer medication fre tion perform local anaesthetic know quently produce customised basis patient wear data glass medical futurist individual patient future picture home approach follow feel ease despite unfa amazon medicine doctor miliar environment author keynote speaker determine right combination researcher active ingredient send data conclusion presentation eg course pharmacy use printer harvard stanford produce customise pill pati radical change yale university singularity ent concern initial trial thing common glance universitys futureme course method successfully appear consequence nasa ame campus complete pill technological revolution actual organisation include break particularly quickly fact reflect cultural revolution big pharmaceutical patient body soon printer sense people company long manufacture heart thing especially pill instance produce voice globally health true patient enjoy entire body part patient care technology dr mesk nership equal protagonist receive transplant feature dozen healthcare needs wish publisher include cnn shape development national geographic forbe healthcare sector trend time magazine bbc healthcare company adapt virtual testing new york times rapid new active change ideally help push ingredient forward welcome new opportunity currently pharmaceutical research com information technology afford panie conduct laborious testing involvement actual ensure new idea imple series trial order test new active patient advantage mente quickly urge reg ingredient process take computer test thousand differ ulatory authority rapid year require participation ent combination active ingredient pragmatic decision large number patient short space time transform selfimage expose certain degree risk identify good one save big company future soon thing past pharmaceutical manufacturer lot increasingly capable safeguard thank computer able time bring new medicine ing success achieve process large amount data expert market fast past require network big datum future new active soon possible use artificial partner foremost ingredient undergo virtual intelligence testing active ingredient patient progress partnership l n g e r p r n e r h p b e n e f p e n partnership increasingly gain importance boehringer ingelheim professor dr dorothee bartel spend month travel usa behalf company order forge close contact doctor healthcare organisation insurer epidemiologist conclusion nowadays cooperation begin early couple year ago objective build genuine trustful longterm partnership progress partnership prof dr dorothee bartel prof bartel exactly different today global head epide quently long ordeal prof bartel previously phar miology boehringer ingelheim right medicine find maceutical company talk hold master patient great strain health insurer pharmacist shortly degree epidemiology possibly lifethreatene launch medicine harvard school public health expensive health insurer mainly commercial issue usa doctorate hanover today seek jointly characterise patient pricing today trustful partnership start medical school germany group early able offer diseaserelate discussion professor epidemiology individual therapy analysis datum productrelate discussion way public health routine clinical practice come play optimally pursue common goal adjunct professor mcgill datum available prior partner help sick people university canada approval example electronic med sonalise medicine ical record claim datum identify characterise patient practical term pharmaceutical unmet medical need launch company notice change prof bartel today health insurer long wish purpose example ve license analyti pay visit doctor prescription medicine cal platform humana fifthlarg health plan increasingly criterion quality usa able work jointly humana patient data treatment successful relationship pharma database license boehringer ingelheim ceutical company mean instead pure volume breach datum protection increase datum s discount insurer negotiate reim pool help search suitable patient subgroup bursement depend effectiveness safety enable close partnershipbase cooperation medicine routine clinical use socalle valuebase framework evidence base medicine contract gain ground paradigm shift volume value model pharmaceutical company go solo way role personalise medicine play prof bartel prefer way general go prof bartel critical nowadays question solo long expedient pharmaceutical company medicine good help health insurer pharmacist provider patient organi individual patient s main reason coopera sation able improve human health tion health insurer pharmaceutical company achieve progress possible joint effort today begin early patient fre trustful longterm partnershipbase cooperation progress partnership p n f r n l h e l h january see union sanofis animal health business merial combine boehringer ingelheim animal health business unit world second large animal health operation employee product available market global presence country progress partnership leader vaccines anti boehringer ingelheim parasitic continue special animal health focus prevention addressing spectrum treatment need aim develop new effective medicine diagnostic disease high unmet medical need continue invest exist marketleading position swine equine pet pet expand offer cattle poultry livestock swine increase exper tise resource offer custom er innovation wider set dr joachim product service want sup hasenmaier member equine board manage director port farmer raise care ani responsibility mal healthy sustainable animal health financially viable way build con fidence consumer know combine strength boehringer ingelheim animal sanofis animal health organi sation improve com healthy petitiveness animal health busi ness strategically important human company complementary portfo global player lio business perfect healthy fit serve customer partner well offer broad range health solution commit help com product available country continue excellent panion animal live long well service delivery customer expect owner today lifelong combine animal health emotional connection pet team commit combined consider family member scale resource deep rd capabili familyowned business tie lead industry improve longterm perspective achieve country animal wellbee welcome merial benefit employee boehringer ingelheim family reflect customer passion animal health com boehringer ingelheim commit share mitment make industry ensure smooth transition poultry well improve human ani business continuity organisation swine pet mal health combine integrate deeply experienced new lead industry player common leadership team draw vision recognise critical boehringer ingelheim merial livestock importance serve animal health ground steer business unit companion animal need globally focus preven strategy bear commitment tion know animal customer partner relationship cattle healthy human healthy innovation equine p r n e r h p b e n r u patient able trust doctor pharmaceutical company ensure provide good possible therapy effective safe medicine boehringer ingelheim striven maintain trust year p r n e r h p b e n r u partnership base trust partnership base trust b c k l f e age anna higgs suffer stroke paralyse body british woman struggle physical psychological effect year know path life easy right partner nna higg look forward nice christmas celebrate christmas day family father house harlow north london annas newborn son henry month old suddenly anna not feel difficulty speaking walk family take home bed follow morning annas sister notice seriously wrong call emergency doctor devas tat diagnosis stroke age partnership base trust point nurse tell d probably need electric wheelchair leave hospital totally knock young mother transfer local hospital harlow week later receive physio therapy day initially concen trate right leg want anna higgs home harlow learn walk quickly pos sible progress slow anna repeatedly suffer bitter setback local hospital harlow contracting hospital infection skeleton staff christmas weaken mean possible point nurse tell d form magnetic resonance imaging mri probably need electric wheelchair scan anna trans leave hospital anna remember ferre hospital away totally knock emergency treatment initial spend month hospital test husband craig parent relative visit old flat floor day anna increasingly local authority find flat desperate long ground floor start par right arm right leg ticularly difficult period anna long sight right eye learn cope everyday life worried say anna despite paralysis ex understand happen tremely difficult small child great fear look say use leave hand entire life hitherto include change henry like look nappy family young son support anna feel possible annas husband craig hospital choice job order people look stay home clear time partnership base trust struggle control leg today anna walk normally partnership base trust despite difficult situation able lot organise thing not use joke anna fight help angel way life despite physical limitation take dancing year ago organise annual dance cabaret aid self help group stroke victim support family relationship hus treatment physiotherapy band craig help anna escape immediately leave hospital deep hole fall communication break com stroke way pletely moment content independent anna cope life easy able rely stroke rise globe complete mental breakdown professional partner leave past year follow year young hospital stroke significant increase number woman long leave house urgently need safety net fall patient million give hope say say need doctor people worldwide affect seriously worried d carer therapist talk patient lack access specialised stroke precisely happen discuss thing follow hospital receive second stroke severe joint plan anna know optimum treatment care expert experience patient estimate roughly minute turning point come hardly capable deal thing stroke patient anna decide antidepressant situation save specialised hospital thing slowly improve look anna actually die suffer complication deep despair fade think lucky compare boehringer ingelheim help ground anna find strength despite bad experience change situation comp any fight iron discipline work young definitely get angel initiative work lead regain control right leg help attention old organisation expert improve son help say want patient true doctor access specialist stroke hospital able treat like therapist friend world initiative aim mother treat child recently friend raise build community motivated struggle buy anna device help new stroke centre special control leg today anna strengthen muscle right leg ise hospital europe walk normally contrast electrical impulse end initiative physiotherapy right arm anna know fact training nurse carer stroke disappointing hardly regain life specialist offer simulationbase day point gave enjoy great extent training equip hospital strength despite difficult situation stroke box keep yearold say year ago able lot organ motto angel initiative right arm tattooed ise thing fortunately give life chance way look nice m open direct person partnership base trust case stroke fast balance eye face loss balance blur vision face stroke headache droop dizziness arm speech time arm leg weakness speech difficulty time ambulance time brain immediately stroke disruption brain function hour insufficient supply brain region oxygen fact stroke clot retrieval treatment increase chance good outcome stroke treatable clog blood vessel stroke complex medical issue cent case blood vessel way significantly clog clot embolus calcifi reduce impact cation arteriosclerosis cause recognize sign stroke early treat medical emergency admission million specialised stroke unit stroke year access well worldwide professional care substantially improve outcome million oxygen cause disability function affect brain area temporarily permanently source wwwworldstrokecampaignorg impair partnership base trust w r k n g g e h e r c b c u n e r f e n g monitor traceability medicine particular importance boehringer ingelheim counterfeit product endanger health patient company work retailer manufacturer medicine secure counterfeiting boehringer ingelheim give high priority pursue suspect case c omplaint result effect experience responsible protection coun suspicion counterfeit unexpected effect short terfeiting boehringer ingelheim occur suspicion product send time year doctor pharma provide doctor patient forward facility manufac cist hospital patient contact counterfeit medicine ture correspond original boehringer ingelheim national subsid order able inve boehringer ingelheim colleague iarie packaging tigate case ask suspi compare packaging tablet look different usual one cious product send retention sample submit batch number expiry date detail able come reliable con product chemical analysis say packaging match clusion case photo schn cent case detail blister pack bot provide initial indication counterfeit suspicion turn unfounded tle label possibly expect ing explain johanne schn amiss partnership base trust range manipulation launch securpharm initiative expiry date packaging securpharm develop sys complete counterfeiting product securpharm work tem unique labelling medicine alien ingredient luckily product packaging datum matrix code familiar portfolio not badly affect train ticket example contain counterfeit manu encrypt information manu facturer say schn facturer medicine batch counterfeiter focus antimalari number expiry date infor al antibiotic lifestyle product mation store central database medicine treat erectile dys soon pharmacist scan pack function dieting aid hair restorer prior sell system check counterfeit medicine represent datum valid record grow problem sale product mean internet make easy criminal sell pack twice trade counterfeit operation explain schn pharmacist pangea coordinate recognise pack incorrect code scan code year interpol seize immediately time counterfeit drug pharmacist scan pack prior sell prohibit medicine enormous lead time value securpharm system test frequently tablet solution contain pharmacy germany active ingredient january product actually contain active boehringer ingelheim feature ingredient low concen code pipeline tration bad eu directive make criminal use toxic kind anticounterfeit system man substance manufacture counterfeit datory enormous lead say schn com supply chain security pany take anticounterfeit boehringer ingelheim invol initiative outside germany enabling ve combat counterfeit medicine example detailed tracking deli year inter parcel pallet special seal database departmental work johanne schn design prevent pack system check datum valid colleague primarily open unnoticed prior sale record sale product undertaking outset boehringer ingelheim put range measure supply emphasis provide information chain medicine secure instance patient detect coun company campaign intensively terfeit number typical implementation new coun warning sign mind seller terfeit protection directive euro trustworthy offer pean union eu european good true pack look federation pharmaceutical industry information tamper association efpia directive spelling mistake text pharmacist recognise original pack implement europe tablet capsule differ immediately february precise usual colour form medicine actu regulation draw eu ally taste smell different usual politician boehringer ingelheim patient sure ask start implementation pharmacist contact manu new regulation pilot facturer directly germany sweden absence effect medicine partnership major com produce unusual effect counter petitor representative feiter try say schn pharmaceutical wholesale pharma hard cist association boehringer ingelheim possible p r n e r n e e p c e balance security space good basis good idea benefit patient principle crucial boehringer ingelheim corporate culture reflect respectful way employee important partner inhouse treat company social commitment improve health worldwide partner need space p w e r e b u r p e p l e partner need space maria tereno global head diversity inclusion discuss boehringer ingelheim corporate culture colleague shawn liu global head human resource hr strategy transformation take motivate young talent role leader play limit individuality diversity perfect thinking ensure pipeline fill tereno mr liu tereno laugh good idea ultimately employee great corporate culture s deci lead market share growth crucial success sive current success liu diversity society work boehringer ingelheim continue successful force simply fact tereno simply come year company oper ignore respond diversity company drive ate worldwide boehringer ingelheim need embrace inclusion culture capacity innovation pharmaceu highly diverse workforce ve inclusion diversity not tical industry increasingly competi people wide range nationality contribute bad tive business important organisation different case lead chaos remain innovative long cultural background age need work environment value term basis s possible group different experience partnership diversity think dedicated motivated employee leverage diversity drive colleague trust liu true successful company focus innovation business growth not need watch particularly people take wellbeing engagement mean tereno exactly diversity mix seriously proud tereno strong diverse team inclusion make mix work company important resource everybody need feel value long time business mat particular generate good idea require inclusive leadership culture ter human pharma animal study company dis leader provide honest con health country matter courage difference workforce structive feedback recognition europe america asia cent marketable achievement simple employee heart idea leave table mainly thank great work company worldwide lack endorsement diversity partner need space learn enable diverse employee achieve good perfor mance liu lead important ambition company different personal family topic moment matter learn enable diverse employee ground good contribu boehringer ingelheim employee achieve good performance tion company simple example numerous interaction company naturally not realistic cre place germany childcare colleague com eat individualised approach flexible working hour possi pany supervisor employee perfor employee cus bility allow time spe mance feedback obvious example tomise employee experience aim cial innovation labs people organisation need identify look different need different meet order work creatively critical moment matter group employee create tailor project way employee deal extremely approach group key project development respond diversity work perform good global diversity inclusion office workforce need provide custom ise employee experience let talk inclusion let turn challenge moment matter successfully establish todays hr work boehringer ingelheim chance engage inclusive culture find young talent organisation tereno leader team need company excellent well consciously demonstrate inclusive reputation behaviour aim foster innovative liu true mean precisely idea secondly organisation need unfortunately tereno people work different continuously create right frame war talent accept way drive different goal work infrastructure people genuine talent able partner need space choose ideal employer not simply sit recruit employee traditional way instead need think sell job opportunity talented people increasingly important particularly paradigm emerge market achieve shift need underline offer work environment value maria tereno diversity challenge interest give people equal access benefit ing role development career tailor choice different people opportunity fact different need different expectation treat employee charge respect boehringer ingelheim size fit good employer award global diversity boehringer ingelheim regularly pick inclusion office surely help march liu certainly helpful particu larly brand perspective brazilian birth not brand japanese portuguese thing actually accumulation root master good effort treat employee business administration boehringer ingelheim like university aspect ve mention toronto join boehringer ingelheim gender diversity female brazil role leadership clude brand management customisation tereno diversity head marketing gender product globally gender visible diversity locally october dimension leverage appoint regional increase gender balance lead business head human ership reflect diverse market pharma japan aus customers cent tralia role healthcare decision family team devel take woman ve great female oped people strategy leadership talent need continue com foster development pany core priority important develop female talent pipeline diversity opportunity leverage different generation range baby boomer age fit enormous knowledge experience millennial age develop career potential talent future partner need space diversity minority individual compliance ethic balance team innovation composition growth diversity mix diversity inclusion make mix work limit diversity liu company value big challenge surely cir hr strategy want cumstance ve colleague liu primarily concentrate tereno course different country strategically area produce chaos shawn different nationality treat cul actually create competitive advan previously mention tural background age gender etc tage boehringer ingelheim effective understand strive equally not room leadership customise employee expe achieve goal oppose value rience diverse inclusive accept need result respect trust empathy passion organisation time need lastly need sure tereno aim set good example run hr like business dayto colleague enjoy work human resource team day activity similar team liu laugh exactly company staff record recruitment meeting involve passionate debate staff benefit exchange customer satisfaction continuous improvement professionalism partner need space concentrating area actually create competitive adv antage shawn liu global head hr strategy transformation boehringer ingelheim january chinese manager hold leadership role boehringer ingelheim country corporate level previously work consult industrial fortune organisation boehringer ingelheim year new role work colleague achieve great effectiveness thank question liu year time d like efficiency work hr like achieve boehringer ingelheim true secure strategic year time pioneer innovator busi role company tereno hope year ness people management time boehringer ingelheim continue long march competitive today effectiveness efficiency front need good talent leverage diver human resource management sity inclusion way attract retain ppaarrttnneerrss nneeeedd ssppaaccee u c c e f r r n history boehringer ingelheim history shape longterm strong successful partnership day social interaction important founder company inter action base respectful trusting cooperation company outside partner mark corporate culture put people partnership arise people ready assist help order mutually progress time important create nece sary space personal development boehringer ingelheim work accord principle year christian boehringer chairman shareholders committee ppaarrttnneerrss nneeeedd ssppaaccee space health accord world health organisation cent mexico rural population mainly rely wood fuel heating cooking burn wood produce large quantity harmful substance small soot particle directly enter lung house poorly ventilate soot concentration exceed time level threat health constantly breath ing soot particle indoor result disease affect mainly woman child example copd asthma lung cancer fondo para la paz charity boehringer ingelheim mexico set goal improve quality life patient respiratory disease tackle cause end boehringer ingelheim instal ecological stove poor community mexico enormously improve life people project reduce greenhouse gas deliver improved carbon footprint partner need space space culture ernst boehringer establish international day ingelheim germany order provide insight life culture nation people annual series cultural event guide visitor history globe greek antiquity modern era partner need space space patient emp owerment boehringer ingelheim employees usa long serve volunteer local americare free clinic people health insurance boehringer ingelheim care foundation americare launch new health coach programme grow com munity conversation unmet need health coach speak span ish english work oneonone patient chronic disease high blood pressure high cholesterol diabete help develop action plan reach health goal space togetherness year people disability boehringer ingelheim employee cele brate togetherness festival company biberach site germany come know exchange view learn year boehringer ingelheim nere local social organisation people disability biberach employee work volunteer project partner need space space good idea use open source technology manufacture electronically control artificial limb low cost funmove team south korea take place good idea make health changemaker competition background project south korea artificial limb generally expensive relation average income level boehringer ingelheim launch competition charitable organisation ashoka partner need space space creativity boehringer ingelheim support people disability paint behinderte menschen malen project initiate state office social affair young people care mainz germany highlight annual exhibition company staff restaurant ingelheim people disability present painting partner need space space family world war boehringer ingelheim begin build flat house near plant site ingelheim germany employee family partner need space space team spirit occasion company th anniversary photomontage company employee picture present workforce albert boehringer hang year desk space rest relaxation company germany boehringer ingelheim introduce pay holiday employee space ideal september albert junior old son company founder write letter brother ernst school time thing advise young brother not ceive ideal solely make money common good example industrialist practice social wel fare worker imprint f u h v e n q u e r e r c e n p l e e n h e e c n c u boehringer ingelheim gmbh binger strae ingelheim germany telephone fax contact corporate division communication public affair email pressboehringeringelheimcom internet wwwboehringeringelheimcom issue boehringer ingelheim gmbh concept design layout mpm corporate communication solution mainz wwwmpmde photo illustration boehringer ingelheim cover adobe stock tim wegner rainer mirau getty image shutterstock science photo library plainpicture stewart turkington dieth schrder fotografie fondo para la paz iap alex ostasiewicz americare st elisabeth stiftungheggbacher wohnverbund sabine haase leave german siedler leave susanne herbst right andreas secci print neue sddeutsche verlagsdruckerei gmbh ulm copyright boehringer ingelheim gmbh right reserve annual report reproduce transmit form mean electronic photocopy permission write boehringer ingelheim gmbh figure party annual report base datum availa ble time financial statement draw wwwboehringeringelheimcom annualreportboehringeringelheimcomb e h r n g e r n g e l h e annual report value innovationf na n ci l h ig h li g h ts u mm ry r ep r amount million eur indicate change net sale region europe americas summary asia australia africa business report prescription medicine consumer health care animal health biopharmaceutical industrial customer sale research development personnel expense average number employee operate income operating income net sale group profit net sale group equity return group equity cash flow investment tangible asset depreciation tangible asset product prescription medicine product consumer health care net sale million eur change net sale million eur change spiriva dulcolax pradaxa buscopan trajenta jentadueto pharmaton micardis mucosolvan v e r v e w company shareholder perspective key aspect group management report consolidate financial statement product portfolio u r c p n boehringer ingelheim group world lead pharmaceutical company headquarter ingelheim germany boehringer ingelheim operate globally affiliate total employee focus familyowned company found research develop manu facture marketing new medication high therapeutic value human veterinary medicine social responsibility important element corporate culture boehringer ingelheim include worldwide involvement social project initiative make health care employee respect equal opportunity reconciliation work family life form foundation mutual cooperation thing company focus environmental protection sustainability c n e n company product portfolio shareholder perspective prescription medicine key aspect respiratory disease corporate body cardiovascular metabolic disease oncology group disease central nervous system management report infectious disease information group report economic position animal health risk report livestock swine report expect development livestock poultry livestock cattle consolidated companion animal horse financial statement companion animal small animal overview major consolidated company consolidate balance sheet consolidated profit loss statement cash flow statement statement change group equity note consolidated financial tatement auditor report h e h r e h l e r p e r p e c v e christian boehringer chairman shareholders committee shareholder perspective independent entrepreneur boehringer ingelheim shareholder aim contribute improve health people animal global workforce people share ambition maxim keep company family ownership maintain independence readiness focus core business secure competitiveness organic growth anchor generation past year characterise agility momentum willingness change time boehringer ingelheim year history phase market shape major change times especially shareholder readiness bear entrepreneurial risk successfully enable employee explore new avenue strength company lie capacity innovation key competitive ness innovation result major step small step value chain shareholder able create longterm reliable framework innovation change borne employee clear target space implementation create foundation employee prepare responsibility adopt new path make personal contribution successful year boehringer ingelheim company record profitable growth success past year success employee result tireless commitment boehringer ingelheim behalf shareholder like opportunity express heartfelt thank sign christian boehringer chairman shareholders committee k e p e c andreas neumann simone menne joachim hasenmaier hubertus von baumbach allan hillgrove michel pairet leave right board manage director key aspect compare group today boehringer ingelheim year ago observe significant change comprehensive transformation focus human pharmaceutical animal health manufacture biophar maceutical product correspondingly develop corporate structure align business unit value innovation drive forward persistently high investment research development previous year proof boehringer ingelheim clear focus innovation value chain change require new network capacity innovation partnership combine crucial success factor seek collaborate partner intensely past goal con tinue significant contribution human animal health future serve customer interest current financial year focus implement step outline acquire merial yearend reach milestone realign ment animal health business outcome month successful effort globally highly competitive organisation integration animal health organisation high priority order consistently expand new market position human pharmaceutical business continuously work safeguard market success new establish medicine innovative concept portfolio fill confidence praxbind bring market country enable doc tor rare emergency situation reverse effect pradaxa oral anticoag ulant minute pradaxa product class offers option key aspect field diabetes continue work highly successfully alliance partner eli lilly company cardiovascular longterm outcome study empareg outcome able demonstrate jardiance treatment type diabete sig nificantly reduce risk die cardiovascular disease approve food drug administration european authority see huge potential jardiance update product information milestone groundbreake expansion biopharmaceutical production site vienna austria want expand considerably com petence develop decade biopharmaceutical production increasingly significant recognise cornerstone company medium term priority development human animal health product portfolio technological development lead fundamental change healthcare sector intend shape long term want achieve significant progress urgent need major therapeutic advance past time able help patient innovative medicine prevention acute treatment stroke parkinson disease severe pulmonary disease lung cancer diabetes draw success confident future ability away fear associate disease alzheimer schizophrenia past year change outline pose significant challenge organ isation entail major personal change people unaffecte enormous additional effort able close financial year successfully like opportunity thank employee commitment creativity passion boehringer ingelheim sign sign sign hhhuuubbbeeerrrtttuuusss vvvooonnn bbbaaauuummmbbbaaaccchhh jjjoooaaaccchhhiiimmm hhhaaassseeennnmmmaaaiiieeerrr aaallllllaaannn hhhiiillllllgggrrrooovvveee sign sign sign sssiiimmmooonnneee mmmeeennnnnneee aaannndddrrreeeaaasss nnneeeuuummmaaannnnnn mmmiiiccchhheeelll pppaaaiiirrreeettt corporate body c r p r e b e shareholders committee board manage director christian boehringer hubertus von baumbach chairman shareholders committee chairman board corporate board division finance christoph boehringer prof dr dr andreas barner erich von baumbach jr chairman board isabel boehringer dr wolfgang baiker corporate board division biopharmaceutical dr mathias boehringer operation prof dr dr andreas barner dr joachim hasenmai corporate board division animal health corporate board division consumer health care advisory board allan hillgrove egbert appel corporate board division chairman advisory board pharma marketing sale trustee martin hilti family trust corporate board division human pharma president hilti foundation kurt beck simone menne ministerpresident corporate board division finance dr nikolaus von bomhard dr andreas neumann chairman board management corporate board division human resource mnchener rckversicherungsgesellschaft dr michel pairet dr andreas kreimeyer corporate board division research member board executive director nonclinical development research executive director basf se corporate board division innovation jan rinnert chairman board management heraeus hold gmbh group management report boehringer ingelheim group management report consolidate financial statement product portfolio g r u p n g e e n r e p r information group report economic position risk report report expect development group management report information boehringer ingelheim group company information group company group management report information group group business model boehringer ingelheim familyowne company treat type diabete significant contribution establish base ingelheim ger boehringer ingelheim success ofev focus company research newly introduce offer people development production sale innovative pharma rare fatal respiratory disease idiopathic pulmonary ceutical improve health quality life contrib fibrosis ipf new treatment option achieve ute great therapeutic benefit human medicine strong growth animal health affiliate company employee worldwide group achieve net business aim boehringer ingelheim continue sale eur billion make drive forward innovative development world pharmaceutical company exist product portfolio organic growth financial year boehringer ingelheim business activity cover prescription medicine consumer health care animal health biopharmaceutical industrial custom net sale business eur million er start exchange boehringer ingel heim consumer health care business chc sanofis prescription medicine animal health business merial take place schedule include figure financial year step mark successful conclusion strategic transaction start exclusive consumer health care negotiation december prescription medicine form core boehringer ingel heim activity medicine boehringer ingelheim animal health long standard treatment cardiovascular disease respiratory disorder oncology disease central nervous system immunology company big revenue contributor biopharmaceutical spiriva treat chronic obstructive pulmo nary disease copd asthma pradaxa prevent stroke patient atrial fibrillation prevention treatment industrial customer sale thromboembolic disorder trajenta jardiance remain impressive trajectory consolidated financial statement product portfolio net sales region eur million boehringer ingelheim achieve majority sale america europe region revenue region asia australia africa aaa gain significance make group total net sale big market usa japan germany account sale year europe research development rd asia line mission statement boehringer ingelheim australia africa primary goal research develop innovative medi america aaa cine therapie treatment disease satisfactory treatment available aim time major contribution area need treatment high occupy lead cooperation external partner ing position major indication area boehringer ingelheim operate global research network major facility biberach hanover ingelheim achieve aim boehringer ingelheim germany ridgefield st joseph usa vienna rd activity draw global network comprise austria support small facility kobe japan academic group public research institution biotech milan italy company addition expand product portfolio partnership agreement systematic consumer health care dulcolax buscopan inlicense technology product year pharmaton mucosolvan compa review example boehringer ingelheim agree long nys good selling medicine past financial year term partnership development nextgeneration oncolytic virus platform austrian company animal health major pillar boehringer ingel viratherapeutic purchase option agreement en heim business swine vaccine ingelvac circoflex titling boehringer ingelheim acquire viratherapeutic treat porcine circovirus type signifi completion phase clinical development not product animal health term sale boost competitiveness area long term boehringer ingelheim rd activity basis boehringer ingelheim acquire animal health business company success innovative prowess merial french company sanofi january primary driver group positive growth recent year inhouse research develop biopharmaceutical business important ment supplement external cooperation partner growth area boehringer ingelheim boehringer ingel ship continue priority future heim biopharmaceutical activity comprise manu facture ownbrand marketable product financial year employ average actilyse metalyse praxbind process devel people rd site total opment new biological entity nbe biosimilar eur billion invest research devel world lead company process opment new medicine correspond development contract manufacture commercial group net sale forecast production thirdparty industrial customer level previous year group management report information boehringer ingelheim group company research development expenditure eur million net sale prescription medicine expenditure eur million prescription medicine net sale average number employee investment tangible asset investment infrastructure eur million human pharmaceutical key treatment goal therapeutic area boehringer ingelheim carry research develop reduce risk exacerbation posthoc analysis ment prescription medicine business wisdom study publish suggest facilities usa germany austria italy japan gradual reduction dosage inhale corticosteroid ic result increase risk exacerbation key focus research work patient continue receive spiriva tiotro follow indication area pium laba salmeterol appear harm small group patient severe severe immunology respiratory disorder copd increase eosinophil blood count frequent cardiometabolic disease cardiovascular exacerbation metabolic disease oncology immunooncology new largescale dynagito study examine disease central nervous system effect spiolto respimat comparison spiriva respimat case copd exacerbation expenditure rd prescription medicine account result expect net sale generate business tovito trial programme wisdom study boehringer ingelheim continue pursue inten current study evidence serve sive research chronic respiratory disorder basis update position paper gold com asthma copd ipf able offer affect mittee global initiative chronic obstructive lung patient good possible treatment disease treatment copd gold update recommend therapy longacting anticholin key goal copd therapy enable patient remain ergic lama longacte betaagonist laba physically active long september find combination include spiolto respimat ing phase iii study physacto present broad range copd patient gold stage b congress european respiratory society er combination spiolto respimat clinical unitinaasthma trial programme physical training change behaviour significantly examine spiriva tiotropium respimat asthma improve functional capacity copd patient complete new datum supplement physacto study form tovito trial exist evidence confirm spiriva respimat programme examine efficacy safety welltolerate effective asthma patient spiolto respimat treat copd continue symptom despite basic therapy consolidate financial statement product portfolio inhale corticosteroid ics andor longacte beta approve use child year age agonist laba old include global strategy asthma management prevention global initiative phase ii largescale unitinaasthma trial pro asthma gina gramme include clinical study worldwide study centre patient include market approval patient child young people age worldwide suffer ipf treat ofev nintedanib new posthoc analysis present annual meeting american academy allergy asthma new analysis pivotal phase iii inpulsis immunology aaaai demonstrate spiriva study inpulsison followup study respimat effective addon therapy addition datum everyday practice provide evidence basic therapy irrespective individual efficacy ofev broad range patient subtype allergic asthma analysis show ofev consistently slow course disease considerable reduction rate datum support publication new fvc decline significantly reduce risk analysis primotinaasthma study show acute ipf exacerbation inpulsison followup spiriva respimat effective independently study confirm sideeffect profile inpulsis broad range baseline characteristic addon case maximum exposure time therapy patient continue display symptom year new safety concern identify despite icslaba june ipf patient pool datum analysis seven study phase ii enrol new study international phase iv study phase iii find safety tolerability profile inmark investigate effect ofev spiriva respimat addon therapy change certain biomarker blood examine ics comparable placebo biomarker predict individual clinical course ipf annual meeting american thoracic society at european respiratory society er datum senscis safety efficacy nintedanib paediatric study unitinaasthma pro systemic sclerosis largestever study sufferer gramme show spiriva respimat effective systemic sclerosis ssc develop interstitial addition basic therapy child young peo lung disease ild connection boehringer ple symptomatic asthma age ingelheim continue pursue commitment child symptomatic asthma examine potential ofev offer form welltolerate age progressive fibrotic interstitial lung disease sep tember european commission ec new datum form application eu food drug administration fda grant usa goal extend indication nintedanib orphan drug status treatment sscild spiriva respimat case asthma july boehringer ingelheim pool cardiovas eu spiriva respimat approve treat cular metabolic disease therapeutic area create ment adult continue display asthma symptom new combine therapeutic area cardiometabolic despite icslaba therapy usa spiriva respimat disease group management report information boehringer ingelheim group company key milestone past year inclusion anticoagulant effect pradaxa update datum empareg outcome study datum product char reverse ad study subanalyse pre acteristics information jardiance empagliflozin sente congress praxbind approve country world include usa country worldwide canada january european commission decide include datum european product indication area oncology boehringer ingelheim characteristic information subanalyse successfully advanced research development empareg outcome study present major pipeline compound market treatment international congress course year aim provide new treatment option offer analysis examine effect jardiance new patient add therapeutic value contribute quality deteriorate kidney disease present ameri life improvement diabete association ada th scientific session publish new england journal medicine huge progress highly competitive time order pursue research lung cancer market continue activity potential jardiance field cardiovascular area research development cancer disease boehringer ingelheim eli lilly announce need treatment high afatinib giotrif initiate new clinical study gilotrif secondgeneration medicine treat sister study intend examine empagli ment specific type nonsmall cell lung cancer flozin treatment chronic cardiac insufficiency nsclc available patient patient diabetes study product market leader market underway company diabete portfolio pro result major study luxlung trial gresse schedule include cardiovascular programme commitment boehringer ingel outcome trial trajenta linagliptin carmelina heim team worldwide play key role carolina jardiance trajenta luxlung study afatinib compare erlotinib jointly market boehringer ingelheim eli lilly tarceva patient squamous cell carcinoma lung improve overall survival rate afatinib field anticoagulation datum clinical therapy demonstrate safety profile compara practice publish pradaxa dabigatran ble previous study datum result etexilat include independent analysis datum approval afanitib new indication clinical practice provide author work datum advanced luxlung study food drug administration initial find present confirm improve profile ing phase ii gloriaaftm register study patient comparison gefitinib iressa present congress course year randomise clinical study pradaxa second half boehringer ingelheim decide redual pci recircuit complete return right joint development marketing recruitment patient result pre olmutinib thirdgeneration active substance sente medical congress provide treatment nsclc hanmi pharmaceutical deci insight efficacy safety profile sion follow reassessment clinical pradaxa study examine patient undergo datum olmutinib consider current pro percutaneous coronary intervention pci stent gress area lung cancer positive egfr implantation redual pci patient atrial mutation fibrillation ablation recircuit praxbind idarucizumab specific drug reversal consolidated financial statement product portfolio boehringer ingelheim second product market order drive forward substance portfo treatment advanced nsclc nintedanib vargatef lio progress boehringer ingelheim approve market worldwide sign global cooperation agreement abbvie examine effect nintedanib type cancer march substance risankizumab bi pivotal lumemeso phase iii study malignant examine immunological disease pleural mesothelioma rare type cancer trigger eg psoriasis crohns disease development contact asbestos period year marketing partnership offer good mean ensure begin medicine reach large possible number right patient achieve potential addition product approve significant progress oncological development pipe active substance early clinical line company establish series development stage show sign offer important partnership strategic agreement e strong therapeutic potential patient side atlantic goal strengthen immunological disease inflammatory bowel e oncology portfolio deliver impor disease lupus nephritis tant result clinical development animal health therapeutic area central nervous system research development work field ani boehringer ingelheim focus research identify mal health boehringer ingelheim concentrate inno function brain responsible key vative vaccine protection livestock pet symptom main psychiatric illness include pharmaceutical product focus schizophrenia alzheimer disease depression treatment pet chronic disease continue operate complex research field facilities usa germany china mexico number company recently suffer japan denmark india focus research new setback confident symptom drug development future therapeutic solu base approach help develop effective therapy tion vaccine base local pathogen useful range disease pathogen variant imperative present focusse initially achieve well key market region local rd production standing biology brain rele facility vant circuitry past year invest expansion research portfolio include substance influence exist facility construction centre disruption glutamatergic signal pathway clinical research china ames iowa usa occur case cognitive impairment establish site animal health research company connection examine substance move new research building offer space phosphodiesterase inhibitor influence transmis employee immediate vicinity sion signal brain camp andor cgmp iowa state university investment demonstrate company commitment intention sustainably boehringer ingelheim active area immu strengthen position animal health nology research development year set invest important therapeutic area large number extensive pivotal clinical study expand capacity launch case group management report information boehringer ingelheim group company successfully complete serve cornerstone production regulatory submission addition human pharmaceutical internal research development external project overarch aim production human phar product assess case integrate maceutical reliable market launch prod portfolio activity preservation exist uct routine care patient highqual product expansion geographical dis ity pharmaceutical competitive price tribution important aspect rd work boehringer ingelheim optimise supply strategy early company begin implement strat globally boehringer ingelheim animal health business egy value chain facility receive new product authorisation motto volume value supply net biopharmaceutical work set rigorously focus flexi boehringer ingelheim commit strategic deci ble year reflect requirement sion actively enter biosimilar business business production facility manufac increase access highquality biolog ture product particular relevance group ics patient world biosimilar increase manufacturing technology require unique exper range treatment option doctor tise operate production facility coun patient health sector provide vital con try year review divide tribution efficiency health care system pharmaceutical chemical biophar world patient benefit currently con maceutical facility production facility centrate particular biosimilar monoclonal medical product antibodie immunology oncology bio similar candidate late clinical development production capacity supplement stage bi biosimilar candidate humira external contract manufacturer primarily focus adalimumab bi biosimilar candidate manufacture product advance avastin bevacizumab stage life cycle ensure reliable com petitive supply prescription medicine consumer november publish result health care product close cooperation external pivotal phase iii study bi study bi partner secure boehringer ingelheim access technol demonstrate similar level efficacy safety ogie currently available internal pro comparison humira adalimumab patient duction portfolio enable focus investment rheumatoid arthritis bi accept product particularly relevant review relevant regulatory authority usa europe fda ema boehringer ingelheim primarily invest publish datum phase study biosimilar additional production capacity respiratory dis candidate bi demonstrate bioequivalence ease product spiriva handihaler respimat bi reference product avastin platform cover increase demand bevacizumab ongoing pivotal phase iii study antidiabetic portfolio boehringer ingelheim invest examine safety efficacy bi com eur million production facility parison avastin patient advance nonsmall mexico city koropi greece cell lung cancer consolidate financial statement product portfolio animal health development service chinese international cus field animal health boehringer ingelheim tomer operation plan primarily active production network comprise quarter facility manufacturing vaccine facility nutraceutical supplement contract man occupational safety environmental ufacturer primarily north central america protection europe construction new chinese protection employee facility facility taizhou continue apace asian environment sustainable use natural location soon join production network major resource promotion environmental awareness component animal health growth strategy major component company mission statement facility focus manufacture vaccine prime importance boehringer ingelheim porcine disease chinese market compliance social environmental aspect anchor corporate philosophy year biopharmaceutical company strive maintain natural resource biopharmaceutical activity boehringer ingelheim advocate environmental awareness germany biberach austria vienna usa fremont outside company observe social ecological china shanghai comprise manufacture concern way ensure achieve brand marketable product actilyse etalyse sustainable economic success future generation praxbind process development nbe biosimilar world lead compa groupwide company develop bind stand ny process development contract manufacturing ard term environmental protection health commercial production thirdparty industrial cus safety work internal guideline reflect respec tomer boehringer ingelheim cover entire tive countryspecific requirement case biopharmaceutical value chain genetic development far standard prescribe law cell follow manufacture active sub stance finish pharmaceutical product boehringer ingelheim corporate department product launch global market supply environment health safety sustainability ehss responsible conceptual focus boehringer use capacity production facility ingelheim characterise negotiation high level boehringer ingelheim meet increase sanofi exchange boehringer ingelheim demand actilyse active substance praxbind consumer health care business sanofis animal health launch market past financial division merial start corporate ehss year follow successful market introduction monitor negotiation order ensure compliance usa europe companys ehss duty care addition comprehensive environmental diligence process industrialscale cell culture facility implement facility regular ehss audits biberach approve manufacture boehringer ingelheim internal facility customer market product expansion project new premise supplier contract manufacturer industrialscale biopharmaceutical production facility likewise ensure compliance site vienna reach milestone international standard pharmaceutical supply chain initi award official permit enable ative psci programme supplement ground break ceremony commercial facil code conduct relevant supplier status ity shanghai china biopharmaceutical environmental protection occupational safety con group management report information boehringer ingelheim group company tinuously review potential improvement average number employee region identify basis america europe sustainability effort take asiaaustraliaafrica aaa independent assessment performance ecovadi award silver medal fur ther example continuous improvement field environmental protection extensive work major success factor positive growth group analyse decontaminate soil ingelheim site innovative motivated staff accordingly germany commit actively develop support employee order well prepare chal contribution reduce global co emis lenge ahead comprehensive training sion set goal reduce system set great store acquisition entire co emission compare technical expertise promote social skill value groupwide green initi ative achieve reduction integration experience cultural floor space date energy saving reduction background personality boehringer ingelheim emission create openness different approach opinion live vision value innovation health safety employee high priority global company important boehringer ingelheim boehringer ingelheim reflect interna diversity market reflect workforce tional safety standard safety culture create work environment embrace diversity practise groupwide safe initiative aim difference pillar corporate cul reduce number workplace accident ture boehringer ingelheim contribute factor roll second wave focus company success safety global sale organisation global accident frequency rate afr amount acci addition competitive salary boehringer ingelheim dent million hour work represent offer stateoftheart benefit employee reduction point benefit include company pension plan flexible homebase work option numerous health employee report relate benefit significant component corpo boehringer ingelheim employ people rate strategy talent management ensure worldwide represents decrease employability staff promote wide range previous year regional perspective number opportunity innovation work motivate staff america reduce mainly sale employee develop individual generics business number employ ees europe increase remain stable vocational training major importance aaa region boehringer ingelheim understand social responsibility company offer career opportuni tie great number young people time secure talented wellqualifie workforce young professional backdrop demographic change young professional start career consolidated financial statement product portfolio boehringer ingelheim germany different social commitment company encourage scientific technical commercial field boehringer ingelheim employee coun young people currently enrol training try work mmh initiative mmh youth venture programme germany project entrepreneurial skill develop work design social entrepreneurship project company aim strengthen appeal actively support mentor workforce initi boehringer ingelheim employer current ative support executive residence eir future employee boehringer ingelheim recip mmh insight india staff development programme ient award effort area network partnership nonprofit organisation receive mark auditor interna social entrepreneur healthcare sector tional independent employer institute major hr programme give young manager opportunity sup category talent strategy executive develop port participant project facility specific ment staff planning performance management period time jointly develop implement project onboarde evidence strong appeal goal develop promote socially aware development opportunity company innovative approach business integrate new employee potential recruit spective approach everyday business social responsibility manufacturer tradition high expertise take social responsibility business activity field stroke therapy prevention boehringer important aspect corporate culture ingelheim promote broad public awareness commitment wellbee patient employee improve care patient organisation family focus range project politic boehringer ingelheim provide infor addition support people need mation cause consequence stroke initiative particularly country region option prevention act case active company company activity emergency year year boehringer focus protect maintain environ ingelheim involve herzenssache ment german chemical industry association schlaganfall take stroke heart awarenessraising present boehringer ingelheim responsible initiative organise project aware care award company power station nessraise event initiative launch ingelheim facility associate longterm improve boehringer ingelheim promote project ment carbon footprint raise awareness atrial fibrillation associate risk stroke improve public perception major pillar social commitment mmh initi herzenssache lebenszeit take life heart ative year boehringer ingelheim awarenessraising campaign germany partnership ashoka global nonprofit organisation boehringer ingelheim foundation aim partnership integrate health association stroke diabete field pro major factor people live world include vide information risk associate family social environment aim widespread disease possibility preven identify support promise idea improve tion event town cities health order achieve make health goal reduce number new case currently promote select social entrepre neur world attempt come improve european system handle stroke effective solution healthcare sector boehringer ingelheim set angel initiative group management report information boehringer ingelheim group company report economic position european stroke organisation eso positive economic development continue goal develop european network clinic germany economic output rise upturn equipped handle stroke support particular significantly great private public consumer spending housing invest boehringer ingelheim actively support ment increase consumer spending research science culture continuously affirm improve situation labour market mean strategy partnership academic institu number people employment increase tion addition support scientific activity scien growth rate rise export fall short tist award annual boehringer ingelheim previous year level reflect sub fen research award neuroscience heinrich due economic recovery process country key wieland prize research biologically active sub trading partner stance system view assume positive eco nomic growth germany continue forecast report economic growth slowdown growth com parison previous year mainly attributable position decrease number work day weak growth global trade prevent eco macroeconomic environment nomic expansion germany global economy grow pre vious year fall slightly short previous average rate inflation price year increase expect trend germany decrease compare previous year measure consumer price index rate infla major industrialise country economic recovery tion eurozone high continue unexpected brexit vote previous year temporarily increase uncertainty financial market effect real economy limited date addition euro major currency eurozone japan especially economic output rise boehringer ingelheim group dollar usd fast production potential expansionary mon japanese yen jpy end year euro etary policy european central bank bank devalue sharply dollar pre japan decision implement negative vious year fluctuate usdeur december interestrate policy expand bond buy pro usdeur overall gramme act stimulus economic situation emerge economy largely stabilise euro fluctuate relatively strongly japa china india particular strengthen economic nese yen past financial year reach output stabilisation commodity price annual high january jpyeur euro devalue end recession sight russia latin america significantly yen course year low jpyeur july follow upward reval global economy expect maintain uation fourth quarter moderate growth rate united states japan eurozone expect maintain sta global pharmaceutical market register growth ble level growth emerge economy financial year trend ongoing process stabilisation expect continue drive rise demand industrialise country consolidate financial statement product portfolio cancer medicine product treatment auto sale eur million america region immune disease antidiabetic medicine represent total sale remain age population industrialise country big market boehringer ingelheim decline increase level prosperity emerge economy sale compare previous year mainly industry growth remain stable albeit slightly sale generics business strong growth weaker previous year record asia australia africa aaa region boehringer ingelheim achieve course business revenue eur million region correspond longterm sustainably successful development form e stable share group total basis securing company independence revenue europe region show high sale growth long term combine stable earning sound eur million reflect pay finance core boehringer ingelheim ment receive development marketing right strategic focus previous year base approach scope company cooperation abbvie principle field immune disease group sale europe year characterise significant change net sale region currency boehringer ingelheim change repre eur million change adjust sente important step company future america completion exchange consumer health care europe business chc sanofis animal health business merial asiaaustraliaafrica turn year big change aaa business portfolio past year transaction significantly improve future market position general sale growth conform expectation sup field animal health establish future port good result clinical trial large global player segment able place promise new product market successfully push ahead wellestablishe product addition ownership generic business hand experience increasingly transfer hikma pharmaceuticals plc difficult market situation constantly challenge mar quarter correspond sale agreement ket access grow price pressure key market sign july usa japan europe overall company assert despite difficult condition company abbvie boehringer ingel lay foundation future growth heim agree longterm global collaboration development compound therapeutic area boehringer ingelheim record operating income immunology eur million corresponding return sale percentage point pre vious boehringer ingelheim record net sale eur year return sale operating income include million financial year correspond significant positive negative extraordinary effect increase compare previous year compare previous year increase figure eur million exchange rate develop absolute term eur million ment foreign exchange market associate exchange rate effect slight impact currency adjust boehringer ingelheim growth rate stand group management report report economic position boehringer ingelheim usa particular sale spiriva fall significantly key figure eur million change price pressure net sale operating income second big sale contributor boehringer return net sale ingelheim anticoagulant pradaxa record sale result operation eur million correspond increase past financial year boehringer ingelheim business level activity divide prescription medicine con sumer health care animal health biopharmaceutical eur million medicine trajenta industrial customer treatment type diabete achieve sale excess billion euro time net sale business currency eur million change adjust prescription medicine ofev offer people rare fatal respiratory consumer health care disease idiopathic pulmonary fibrosis ipf new treat animal health ment option achieve product authorisation biopharmaceutical generate sale eur million industrial customer sale net sale eur million change prescription medicine spiriva total revenue prescription medicine pradaxa main pillar boehringer ingelheim business trajenta jentadueto activity revenue prescription medicine micardi amount eur million equivalent change currency adjust com regard regional distribution sale amer pare previous year successful ica share far placement innovative product good market large market region boehringer ingelheim position establish medicine positive sale growth generate net sale eur million corre receipt payment agree scope spond change compare previous company cooperation abbvie field year currency adjust impact immune disease continue experience sale generics business increase price pressure particularly estab lishe medicine number major market overall secondbigg market europe account boehringer ingelheim able assert revenue eur million sale increase difficult environment lay compare eur million foundation growth subject significant exchange rate effect net sale region previous year spiriva treat chronic eur million change obstructive pulmonary disease copd america big contributor sale achieve reve europe nues eur million reporting period asiaaustraliaafrica aaa fall short level previous year eur million company big sale market consolidated financial statement product portfolio asia australia africa aaa region achieve sale adjust compare previous year achieve eur million equivalent total sale eur million total sale prescription medicine region show increase compare year animal health currency adjust revenue product animal health business increase eur million corresponding consumer health care increase previous year currency consumer health care sale increase com adjust sale product livestock account pare previous year currency adjust large share eur million corresponding business boehringer ingelheim generate reve entire animal health segment nue amount eur million pet segment revenue amount eur million net sale eur million change big sale contributor consumer ingelvac circoflex health care segment dulcolax buscopan ingelvac prrs pharmaton mucosolvan products generate metacam revenue significantly eur million duramune previous year dulcolax big seller sale eur million buscopan show increase past financial year growth animal health segment sig generate sale eur million positive result nificant america region accounting achieve pharmaton sale increase total sale big sale market boehringer eur million ingelheim business grow currency adjust eur million market net sale eur million change important country boehringer ingelheim sale dulcolax increase eur million buscopan pharmaton boehringer ingelheim see revenue grow europe mucosolvan increase eur million rise currency adjust accounting region europe generate high sale total revenue animal health business sale increase eur million correspond share country particularly germany global sale consumer health care business sale year increase currency adjust aaa region report positive growth compare aaa region end financial year sale previous year recording sale eur mil amount eur million increase lion correspond boehringer compare previous year currency adjust ingelheim total animal health sale china particular market account able achieve growth net sale boehringer ingelheim consumer health care business amount eur million america region large sale market consumer health care business end financial year raise revenue currency group management report report economic position boehringer ingelheim biopharmaceutical change interest rate relate conversion sale biopharmaceutical contract manufactur average interest rate discount pension plan ing amount eur million represent growth obligation compare previous year income taxis develop line operate industrial customer sale financial result increase eur million tax industrial customer business consist expense amount eur million increase party business field pharmaceutical chem comparison eur million particularly result ical production sale pharma chemical sale high result company provision eur million achieve correspond tax risk note regard increase revenue compare provision german commercial law shareholder previous year sonal taxis arise group business activity recognise tax expense instead tax presentation expenditure income present withdrawal group equity operating expense boehringer ingelheim increase take extraordinary effect account actual eur million financial year repre tax ratio markedly high figure show senting rise compare previous year profit loss statement cost material higher previous year eur million come eur million financial year group profit boehringer correspond cost material ratio make ingelheim total eur million corresponding personnel expense amount eur million increase previous year level correspond personnel cost ratio eur million percentage point low pre vious year financial position boehringer ingelheim financial management instrument depreciation amortization record increase method aim secure liquidity minimise eur million eur million oper financial economic risk optimise cost ating expense rise compare previous capital appropriate capital structure finan year come eur million item cial activity gear support cost category include commission licence pay business strategy ment dependent sale global company exchange rate volatility signifi operating income amount eur million not impact boehringer ingelheim financial perfor previous year eur mil mance importance business asso lion influence significant positive nega ciate supply relationship mean exchange rate tive extraordinary onetime effect sale generic development dollar constitute great indi business license payment abbvie expense legal risk vidual risk framework groupwide financial adjust effect previous year report foreign exchange risk calculate hedge level operate income meet expectation derivative financial instrument nature scope measure set group guideline report period financial result amount regularly discuss approve relevant eur million eur million committee standardise process previous year largely effect consolidated financial statement product portfolio investment great importance boehringer ingel cash flow lead increase liquidity eur mil heim strategic point view continuous investment lion eur million requirement longterm success develop ment company form basis profita net asset ble growth business division financial year boehringer ingelheim total asset amount eur million increase total eur million invest tangible eur million compare pre intangible asset year review vious year tangible intangible asset total eur million financial year boehringer ingelheim invest eur million expansion production end year financial investment amount capacity respimat soft mist inhaler dort eur million correspond increase mund ingelheim facility germany boehringer eur million previous year value invento ingelheim microparts gmbh dortmund manufacture rie show growth eur million trade respimat soft mist inhalation system receivables decline eur million eur fill relevant active substance million liquid fund include security pharmaceutical production facility ingelheim ready current asset stand eur million previous year global sale eur million boehringer ingelheim invest signifi aforementioned change cash cash not growth market china group continue equivalent group equity amount eur mil investment programme expansion biopharma lion fully cover tangible ceutical animal health manufacturing facility intangible asset addition equity pension pro shanghai taizhou visions longterm liability available group long term total item investment research facility germany amount eur million represent austria usa reflect priority share total asset consequently longterm research development field human disposable capital cover intangible tangible asset animal medicine boehringer ingelheim inventory trade receivables cash flow amount eur million provision higher year represents decline cash flow eur million liability reduce operating activity increase eur million eur eur million previous year million mainly receipt payment agree scope company coop status show financial position remain eration abbvie field immune disease resoundingly positive balance sheet previous year mean investment respective balance sheet ratio sum boehringer finance entirely fund generate company ingelheim net asset financial earning position total eur million invest tangible confirm credential soundly finance profita assets eur million intangible asset term ble company cash flow financing activity record flow fund amount eur million mainly loan repayment overall change group management report risk report boehringer ingelheim risk report individual risk important risk boehringer ingelheim risk opportunity management expose broken follow specific cat aim risk management system implement egorie financial risk legal risk production environ boehringer ingelheim identify businessspecific risk mental risk personnel risk sectorspecific risk particular risk jeopardise continue exist ence company early possible assess risk identify concrete reduce reasonable level mean suit appear controllable mean specific manage able measure ment procedure term abstract case risk completely control assess risk context holistic risk mean target management procedure regardless management endeavour account probability occurrence result opportunity opportunity management base strategy objective company individ financial risk ual business operate business unit inte relevant financial risk break gral groupwide planning management follow currency risk credit countryspecific risk system responsible business func management financial investment risk tion bear direct responsibility early systematic identification analysis use opportunity currency risk boehringer ingelheim researchdriven innova global orientation business activity result tive pharmaceutical company current research currency risk exchange rate volatility particularly development activity naturally consider relevant regard dollar japanese yen group opportunity relevant project illus monitor quantifie risk regular interval trate research development chapter make predictable future business mean relevant hedging strategy appropriate financial person responsible key business func instrument forward exchange contract tion include process calculate assess resultant risk subsequently designate con ing risk groupwide risk information system crete controllable ensure identify risk analyse assess carefully follow appropriate classification credit countryspecific risk category adequate countermeasure initi boehringer ingelheim expose credit ate implementation consistently monitor countryspecific risk result international business activity portfolio trade account receivable year review internal auditing perform tar trade account payable identify get routine audit extraordinary audits extraordinary risk group usual level world addition adherence legal requirement sector apply possible default risk internal group guideline main focal point receivables largely hedge economic functionality system effectiveness internal risk continue carefully track credit coun control prevention loss assets effi tryspecific risk position respond negative ciency structure process correspond adjust change timely manner risk ment optimisation initiate necessary regard concrete consolidated financial statement product portfolio management financial investment risk breach take necessary precaution allow group pursue defensive investment strategy detect threat early stage commence management financial asset reflect appropriate countermeasure defend legal position orientation portfolio focus euro legal mean available risk pean economic monetary union emu government regard concrete bond credit rating shortterm investment select bank result concrete production environmental risk controllable risk quality management system compliance pro cesse continuously optimise close cooperation legal risk relevant authority order ensure compli business activity group expose legal ance cgmp standard current good manufacturing risk distinction regulatory liability practice future risk area continue patent protection risk high significance group classify abstract regulatory risk boehringer ingelheim expose risk arise legal order guarantee supply product dispute proceeding official investigation market implement measure guarantee legal administrative decision ongoing future reliable highquality supply internal external proceeding predict regard resultant customer addition supplier management risk abstract procurement involve build internal standby capacity result risk concrete liability risk marketing sale pharmaceutical expose risk area environment health safety sus potential product liability risk boehringer ingelheim tainability ehss preemptively minimise currently product liability insurance company ensure global adherence high safety standard risk profile absolutely guarantee appropriate emergency plan draw insurance coverage maintain reason possible incident kind practise sub able cost acceptable condition sufficient jecte comprehensive quality test regular inter protect boehringer ingelheim claim loss val result measure risk class potential claim loss concrete furthermore product liability claim tie sub personnel risk stantial financial resource management capacity boehringer ingelheim company expose detrimental company image event demographic change resultant risk affect market consider product unsafe ineffec lack appropriately qualified personnel risk tive result unexpected effect regard substantial impact company business risk abstract activity potential risk include longterm planning process year patent protection risk acquire strategic significance result boehringer protection innovation trademark brand ingelheim counter risk mean comprehensive patent right particular importance boehringer personnel concept regardless ethnic background ingelheim research company commercial pro gender religion offer company employee devel tective right increasingly target attack opment opportunity base vocational skill social group management report risk report boehringer ingelheim report expect development report expect expertise personal aptitude willingness responsibility accordance need com development pany view countermeasure describe risk regard concrete year review intense challenge sectorspecific risk time boehringer ingelheim lay boehringer ingelheim expose business risk specific foundation sustainable development long pharmaceutical industry risk mate term growth company major decision rialise past financial year change health care system usa increase significance consistent focus business innovationori result impact boehringer ingelheim ente field attest strategic exchange sanofis continue class abstract animal health business merial boehringer ingel heim consumer health care business chc contract addition loss exclusivity product estab exchange sign june trans lishe market risk associate devel action successfully close january opment registration new product risk transaction improve competitiveness ani increasingly include change restrictive require mal health business industry important growth ment relate pricing reimbursement market establish large sale market frequently price pharmaceutical global player business able offer product subject state monitor customer worldwide innovation regulation price pressure cheap add value high level pool comple generic drug cause state reimbursement sys mentary product portfolio merial boehringer tem boehringer ingelheim keep close ingelheim exist technology platform vaccine eye change sale market antiparasitic pharmaceutical speciality respond current development respec product tive costsave efficiencyimprove measure increase political unreliableness volatility overall statement risk situation difficult market environment increase unpredict current perspective aware risk ability business pose major challenge conjunction risk lead entire pharmaceutical industry continue require impairment company asset financial position significant attention boehringer ingelheim earning jeopardise continued exist regard competitiveness ence boehringer ingelheim important retain scope growth innovation continue successful market future regard change healthcare system increase price pressure particularly establish medicine major market regard increase challenge market access new product expect low growth impetus pharmaceutical industry come year boehringer ingelheim assert despite difficult condi consolidated financial statement product portfolio tion lay foundation growth cost base order create potential investment integration merial business assume secure company longterm success sale animal health division difficult market environment hand double compare previous year potential result measure introduce countervail effect promise new product launch sale company consumer health care business plan operating income special sanofi significant contribution factor year level base current considerable yearonyear increase revenue business structure result expect expect overall term current financial year considerable impact major oneoff effect adjustment currency effect result essentially sale consumer health care business simultaneously acquisition research development cost remain high sanofi animal health business overall anticipate keep strategy drive growth promote strengthen overall group financial capability new product future primarily product integrate merial business research development facility invest area care close investigation thera familyrun company boehringer ingelheim primary peutic benefit associate prospect success aim maintain firm independence competi comprehensive portfolio prospective product tiveness longterm sustainable organic promising study outcome newly approve growth take precedence shortterm profit tar product significant sale potential justifie high get confident achieve ambitious level investment research development target thank great innovative strength base plan invest research development new comprehensive portfolio prospective product global pharmaceutical product similar level year presence support highly qualified moti review base current business structure vate employee current product launch expansion emerge market boost growth area addition patent expiry attack patent business stand vision value major challenge face researchdriven pharmaceutical innovation research develop innovative product industry increase investment rd offer high medical benefit bring big hurdle increase cost associate market aim endeavour new medi product approval context increas cine available enable doctor treat patient ing cost pressure healthcare system effectively currently possible singled particular lead decrease willingness adequately recognise large amount invest development new medicine result price pressure major market prescription medicine conjunction long plan development cycle new product make business predictable require recognise seize opportunity quickly hand subject strategy structure continual monitoring adjustment end instigate initiative past year accelerate reaction change reduce organisational complexity low consolidated financial statement boehringer ingelheim consolidate financial statement product portfolio c n l e f n n c l e e n overview major consolidated company consolidate balance sheet consolidated profit loss statement cash flow statement statement change group equity note consolidated financial statement auditor report overview major consolidated company boehringer ingelheim overview major consolidated company c h boehringer sohn ag co kg boehringer ingelheim boehringer ingelheim boehringer ingelheim gmbh europe gmbh international gmbh germany p r austria p r austria r boehringer ingelheim boehringer ingelheim rcv forschungsinstitut fr molekulare pharma gmbh co kg gmbh co kg vienna pathologie gesellschaft mbh ingelheim vienna boehringer ingelheim boehringer ingelheim pharma gesmbh vienna vetmedica gmbh ingelheim belgium boehringer ingelheim micropart gmbh dortmund czech republic scs boehringer ingelheim comm v brussels boehringer ingelheim boehringer ingelheim sro biopharmaceutical gmbh prague ingelheim china p boehringer ingelheim veterinary finland boehringer ingelheim research center gmbh co kg international trading shanghai hanover boehringer ingelheim co ltd shanghai finland ky espoo philippines norway boehringer ingelheim boehringer ingelheim phil inc manila norway ks asker poland boehringer ingelheim spzoo warsaw distribution p production r research development sole personally liable manage shareholder boehringer ag product portfolio c h boehringer sohn grundstcksverwaltung gmbh co kg boehringer ingelheim auslandsbeteiligungs gmbh argentina r france p netherlands p taiwan boehringer ingelheim sa boehringer ingelheim boehringer ingelheim bv alkmaar boehringer ingelheim buenos air france sas paris taiwan ltd taipeh boehringer ingelheim animal health operation bv alkmaar australia greece p thailand boehringer ingelheim pty ltd boehringer ingelheim ellas ae new zealand boehringer ingelheim north ryde athens thai ltd bangkok boehringer ingelheim nz ltd auckland brazil p india turkey boehringer ingelheim brasil boehringer ingelheim portugal boehringer ingelheim ilac quimica e farmaceutica ltda india private ltd mumbai ticaret istanbul paulo boehringer ingelheim lda lisbon solana agro pecuaria ltda unilfarma lda lisbon indonesia p united kingdom arapongas pt boehringer ingelheim boehringer ingelheim ltd singapore indonesia jakarta bracknell canada boehringer ingelheim boehringer ingelheim singapore pte ltd singapore ireland usa p r canada ltd burlington boehringer ingelheim boehringer ingelheim corp south africa ireland limited dublin ridgefield connecticut chile boehringer ingelheim pty ltd boehringer ingelheim boehringer ingelheim ltda randburg pharmaceuticals inc italy p r santiago de chile ingelheim pharmaceutical pty ridgefield connecticut boehringer ingelheim ltd randburg boehringer ingelheim italia spa reggello usa corporation china p bidachem spa ridgefield connecticut south korea boehringer ingelheim shanghai fornovo giovanni boehringer ingelheim pharmaceuticals co ltd shanghai boehringer ingelheim korea ltd vetmedica inc boehringer ingelheim china seoul st joseph missouri japan p r investment co ltd shanghai boehringer ingelheim boehringer ingelheim vetmedica nippon boehringer ingelheim spain p fremont inc china investment co ltd shanghai co ltd tokyo fremont california boehringer ingelheim animal health ssp co ltd tokyo boehringer ingelheim espaa sa barcelona operations china co ltd taizhou boehringer ingelheim vetmedica japan co ltd boehringer ingelheim sa barcelona colombia p tokyo europharma sa barcelona boehringer ingelheim boehringer ingelheim sa seiyaku co ltd yamagata laboratorios fher sa barcelona bogot boehringer ingelheim japan inc tokyo sweden denmark p boehringer ingelheim ab stockholm boehringer ingelheim mexico p r danmark copenhagen boehringer ingelheim switzerland promeco sa de cv boehringer ingelheim ecuador mexico city schweiz gmbh basel boehringer ingelheim vetmedica boehringer ingelheim del ecuador pharmaton sa lugano sa de cv guadalajara cia ltda quito consolidate financial statement consolidate balance sheet boehringer ingelheim consolidate profit loss statement c h boehringer sohn ag co kg ingelheim consolidate balance sheet asset millions eur note intangible asset tangible asset financial asset fix asset inventory account receivable asset security cash cash equivalent current asset defer charge prepaid expense defer taxis total asset liability equity millions eur note shareholder capital group reserve balance sheet currency conversion difference group profit equity attributable parent company noncontrolle interest group equity difference capital consolidation provision account payable loan liability defer charge defer taxis total liability equity explanation relevant section note consolidated financial statement product portfolio c h boehringer sohn ag co kg ingelheim consolidated profit loss statement million eur note net sale change finish good work process work capitalize operating income total revenue cost material personnel expense amortisation intangible asset depreciation tangible asset operating expense operate income financial income hold income income taxis income taxis income taxis net income noncontrolle interest group profit explanation relevant section note consolidated financial statement legal requirement disclosure shareholder personal taxis arise consolidated business activity tax expense allow taxis show withdrawal accrue group capital consolidated financial statement cash flow statement boehringer ingelheim tatement change group equity c h boehringer sohn ag co kg ingelheim cash flow statement million eur income taxis include thirdparty share amortisation intangible asset depreciation tangible asset change provision pension cash flow change provision noncash income expense income divestiture consolidate company gain loss disposal fix asset change inventory change account receivable asset relate investing financing activity change trade account payable liability relate investing financing activity interest income interest expense net income investment incomeexpense extraordinary magnitude significance income tax cash receipt extraordinary magnitude significance income taxis pay cash flow operating activity investment intangible asset investment tangible asset investment noncurrent financial asset proceed disposal tangible asset proceed disposal noncurrent financial asset cash receipt divestiture consolidate company interest receive income dividend cash flow investing activity product portfolio c h boehringer sohn ag co kg ingelheim cash flow statement million eur cash receipt grant interest pay cash payment owner parent entity cash repayment loan cash flow financing activity change liquid fund cash relevant transaction change liquid fund exchange rate movement financial fund financial fund excl fixedasset security liquid fund security fix current asset source fund use fund statement change group equity equity attri thereof butable non thereof shareholders accrue currency parent control currency group millions eur capital group capital effect company interest effect equity balance contribution withdrawal net income change balance contribution withdrawal net income change balance shareholder capital consist equity c h boehringer sohn ag co kg c h boehringer sohn grundstcksverwaltung gmbh co kg capital consist limited partner capital contribution shareholder personal taxis arise consolidated business activity show withdrawal accrue group capital item statement change equity value round millions eur disclose shareholder capital include limited partner december negative capital account limited partner eur million show net item consolidated retain earning liability limited partner reinstate eur consolidated financial statement note boehringer ingelheim c h boehringer sohn ag co kg ingelheim note consolidated financial statement principle method general principle consolidate financial statement boehringer ingelheim financial year prepare accordance section german commercial code hgb line legal requirement prepare consolidated financial statement group management report section et seq hgb provision german act transformation eu directive bilrug apply time accordance section hgb consolidated financial statement consist consolidated balance sheet consolidated profit loss statement note consolidated financial statement cash flow statement statement change equity consolidated financial statement prepare euro accordance section conjunc tion section hgb improve clarity transparency consolidated financial statement individual item con solidate balance sheet consolidated profit loss statement combine item present explain separately note additional disclosure require individual item find note registry information parent company register c h boehringer sohn ag co kg headquarters ingelheim commercial register mainz district court number hra information company include consolidation parent company boehringer ingelheim group c h boehringer sohn ag co kg ingelheim boehringer ag ingelheim sole personally liable manage shareholder company c h boehringer sohn ag co kg c h boehringer sohn grundstcksverwaltung gmbh co kg general partner control c h boehringer sohn ag co kg boehringer ingelheim group consist total affiliated company germany abroad addi tion c h boehringer sohn ag co kg c h boehringer sohn grundstcksverwaltung gmbh co kg company c h boehringer sohn ag co kg directly indirectly hold majority voting right include consolidated financial statement consolidation rule product portfolio accordance section hgb company include consolidation report ing year individually collectively insignificant term net asset financial position group earning total sale equity net income year company include consolidation account aggregated group financial statement total company ongoing restriction control term article association company consolidate accordance section hgb associate company value equity accordance section hgb lack significance total number affiliate company decrease compare previous year company found company sell company merge company liquidate usamerican company roxane laboratories inc ohio boehringer ingelheim roxane inc ohio sell effective date th februar day sale net asset compa ny amount eur million comprise tangible intangible asset amount eur million inventory amount eur million receivables asset amount eur million provision amount eur million liability amount eur million effect sale company comment respective note profit loss statement significant follow subsidiary exempt report disclosure obligation section hgb boehringer ingelheim gmbh ingelheim boehringer ingelheim europe gmbh ingelheim boehringer ingelheim secura versicherungsvermittlung gmbh ingelheim boehringer ingelheim grundstcksgesellschaft mbh ingelheim boehringer ingelheim finanzierung gmbh ingelheim boehringer ingelheim rd beteiligung gmbh ingelheim boehringer ingelheim venture fund gmbh ingelheim boehringer ingelheim invest gmbh ingelheim follow subsidiary company exempt duty prepare disclose annual financial statement management report accordance section b hgb c h boehringer sohn ag co kg ingelheim c h boehringer sohn grundstcksverwaltung gmbh co kg ingelheim boehringer ingelheim pharma gmbh co kg ingelheim c h boehringer selbstmedikation kg ingelheim boehringer ingelheim veterinary research center gmbh co kg hanover consolidated financial statement note boehringer ingelheim consolidation method inventory fix asset receivables liability income expense item transaction company include consolidation eliminate debt consolidation procedure accordance section hgb procedure eliminate intercompany profit accordance section hgb income expense consolidation procedure accordance section hgb revaluation method apply include subsidiary company consolidation time accordance section hgb company include consolidation time date company subsidiary carrying share hold parent company offset correspond equity subsidiary equity carry fair value asset liability prepay expense defer income special reserve include consolidated financial statement time consolidation remain balance offset capitalise goodwill currency translation asset liability result foreign currency transaction translate average spot exchange rate balance sheet date realisation principle section conjunction section halfsentence hgb historical cost convention section conjunction section sentence hgb apply item remain term year consolidated financial statement financial statement foreign subsidiary domicile state outside eurozone denominate foreign currency convert euro accordance section hgb modify closing date rate method modify closing date rate method asset liability item annual financial statement prepare foreign currency translate euro average spot exchange rate balance sheet date exception equity translate historical rate item include profit loss statement translate euro average rate result translation difference generally report consolidated equity reserve balance sheet currency conversion difference annual financial statement country hyperinflation expect foreign currency effect recognise currency translation accordance section hgb financial statement ii level improve true fair view consolidate financial statement exchange rate group important currency change follow report year basis eur closing rate average annual rate dollar japanese yen pound sterle canadian dollar product portfolio accounting policy fix asset acquire intangible asset tangible fix asset carry cost scheduled straightline amortisa tion depreciation determine consideration technical economic circumstance base follow useful life intangible asset year building year technical equipment machinery year equipment operate office equipment year straightline depreciation amortisation consolidated financial statement additional writedown record reflect impairment value asset consider permanently impair production cost include material labour manufacturing cost appropriate portion material labour overhead depreciation fix asset extent cause production capitalise intangible asset finite useful life useful life year apply goodwill boehringer ingelheim korea ltd acquire past experience product sale market business condition boehringer ingelheim korea ltd indicate present true fair view financial asset essentially include shareholder right security loan carry low cost fair market value impair current asset prepaid expense inventory carry low cost fair market value raw material consumable supply capitalise low average acquisition price fair market value balance sheet date finish good work progress measure production cost basis individual calculation take account directly attributable cost material direct labour cost special direct cost appropriate share production material overhead cost depreciation good resale value lower purchase cost fair market value identifiable risk inventory asset arise aboveaverage storage period diminish marketability low replacement cost take account record appropriate valuation adjustment inventory value lossfree ie deduction expect sale price reflect cost incur consolidated financial statement note boehringer ingelheim receivables asset recognise cost allowance specific risk general credit risk lowinter noninterestbeare receivables term year discount security classify current asset include security recognise low cost quotedmarket price report date cash cash equivalent consist cash balance bank cheque recognise low cost fair market value defer charge prepaid expense record accordance section hgb include expense pay advance respect define period time balance sheet date defer charge record accordance section hgb include proceed represent income respect define period time balance sheet date difference capital consolidation difference capital consolidation recognise follow acquisition march august value net asset acquire exceed purchase price pay value negative difference acquisition company amount eur million january increase acquisition company acquire august eur million negative difference acquisition company amortise estimate period year release negative difference acquisition company eur mil lion financial year eur million show operate income release consistent depreciation amortisation excess asset date acquisition product portfolio group reserve group reserve include retain earning consolidate subsidiary prior year consoli dation entry affect earning relate previous year provision tax provision provision include uncertain liability expect loss executory con tract carry require settle obligation base reasonable prudent com mercial judgement ie include future cost price increase provision remain maturity year discount matchedterm average market interest rate case pen sion provision interest rate result year case provision seven year accordance rckstellungsabzinsungsverordnung german regulation discount provision liability liability recognise settlement defer taxis calculate defer taxis arise temporary quasipermanent difference carry amount asset liability prepay expense defer charge commercial balance sheet carrying amount tax purpose tax loss carryforward amount result tax benefit expense time difference reverse measure tax rate specific respective consolidated company defer tax balance discount difference consolidation measure accordance section hgb measure company specific tax rate applicable time expect reversal difference defer tax asset loss carryforward take account likely year defer tax asset liability report offset consolidated financial statement note boehringer ingelheim note consolidated balance sheet intangible asset acquire concession advance millions eur similar right goodwill payment total procurementmanufacture cost balance currency conversion difference change consolidate company addition disposal reclassification balance currency conversion difference change consolidate company addition disposal reclassification balance accumulate depreciation balance currency conversion difference change consolidate company addition writeup disposal reclassification balance currency conversion difference change consolidate company addition writeup disposal reclassification balance book value book value product portfolio tangible asset advance technical facility payment land facility operating construction million eur building machine equipment progress total procurementmanufacture cost balance currency conversion difference change consolidate company addition disposal reclassification balance currency conversion difference change consolidate company addition disposal reclassification balance accumulate depreciation balance currency conversion difference change consolidate company addition writeup disposal reclassification balance currency conversion difference change consolidate company addition writeup disposal reclassification balance book value book value consolidate financial statement note boehringer ingelheim financial asset investment loan investment affiliate affiliate relate advance investment million eur company company company payment security loan total procurementmanufacture cost balance currency conversion difference change consolidate company addition disposal reclassification balance currency conversion difference change consolidate company addition disposal reclassification balance accumulate amortisation balance currency conversion difference change consolidate company addition writeup disposal reclassification balance currency conversion difference change consolidate company addition writeup disposal reclassification balance book value book value previous year loan item include loan shareholder product portfolio inventory million eur raw material supply unfinished good finish good good resale advance payment supplier account receivable asset residual residual term term millions eur year year trade account receivable receivables affiliate company receivables related company asset asset item include receivables shareholder eur million previous year eur million receivable affiliate company exclusively consist receivables loan receivables related company essentially consist trade account receivable provision million eur pension provision similar obligation tax provision provision consolidated financial statement note boehringer ingelheim provision pension similar obligation provision pension similar obligation determine basis actuarial calculation project unit credit method take account future adjustment salarie pension addition local biometric datum eg germany mortality table g publish prof dr klaus heubeck pension obligation significant country calculate basis follow actu arial parameter december germany usa japan discount rate salary increase pension increase discount rate determine reference average market rate year maturity accordance german regulation discount provision march interest rate discount significant foreign pension obligation usa japan determine comparable param eter line german regulation discount provision march difference calculate accordance section hgb amount eur million equiv ilant result modify period interest discount rate seven year offset income plan asset interest expense result increase provision plan asset intend solely cover pension similar obligation unavailable cred itor plan asset define section sentence hgb measure fair market value essentially derive stock market price offset underlie pension similar obliga tion fair market value plan asset balance sheet date eur million relate pension obligation similar obligation eur million gain loss plan asset interest expense relate pension similar obligation offset accordance sec tion sentence hgb total eur million earning plan asset eur million inter est expense relate pension similar obligation include financial result tax provision tax provision include provision double taxation risk significantly increase follow implementation national tax law action plan organisation economic cooperation development oecd international initiative know action plan base erosion profit shift bep product portfolio account payable loan residual term residual term greater great million eur year year year year bank loan account payable trade account payable advance payment receive account payable affiliate company account payable relate company liabilitie taxis eur million social security liability eur million previous year liability secure mortgage similar collateral right balance sheet date end year liability shareholder eur million previous year eur million present liability account payable affiliate company include loan amount eur million previous year eur million trade account payable amount eur million previous year eur million consolidated financial statement note boehringer ingelheim note consolidated profit loss statement structure consolidated profit loss statement base total cost format taxis include operating expense report net sale comparable figure previous year result firsttime application german act transformation eu directive bilrug section hgb follow bilrug amendment apply previous year net sale previous year amount eur million operating income decrease order provide well insight earning position expenditure service reclassify operating expense material expense improve comparability previous year figure adjust eur million revenue include eur million oneoff payment receive connection cooperation agreement operating income include exceptional income sale subsidiaries eur million addition group result fiscal year impact expense increase provision legal tax risk eur million net sale business business segment million eur prescription medicine consumer health care animal health biopharmaceutical industrial customer sale geographic region millions eur europe germany americas usa asia australia africa japan net sale reporting period include net sale deconsolidate company roxane laboratories inc ohio boehringer ingelheim roxane inc ohio amount eur million previous year eur million product portfolio operating income operating income include income currency translation eur million previous year eur million cost material million eur cost raw material supply good resale expenditure service cost material reporting period include cost material deconsolidate company roxane laboratories inc ohio boehringer ingelheim roxane inc ohio amount eur million previ ous year eur million personnel expense million eur wage salarie social benefit retirement benefits retirement benefit interest effect measurement provision pension similar obligation show separate item financial income average headcount production administration marketing sale research development apprentice amortisation intangible asset depreciation tangible asset amortisation intangible asset depreciation tangible fix asset include extraordinary writedown eur million previous year eur million operating expense operating expense include expense currency translation eur million previous year eur million consolidated financial statement note boehringer ingelheim addition operating expense include increase provision legal risk restructure thirdparty service research development medicine marketing purpose administrative expense fee contribution commission rent freight expense repair carry party operating expense report period include operate expense deconsolidate company roxane laboratories inc ohio boehringer ingelheim roxane inc ohio amount eur million previous year eur million financial income millions eur interest expense relate pension similar obligation provision interest expense similar expenditure interest expense similar expenditure amortisation loss disposal financial asset shortterm investment income investment security longterm loan interest income similar proceed hold income million eur writeoff financial asset income relate company disposal related company income taxis million eur income taxis defer taxis current income taxis essentially include corporation trade tax expense company include consolidation result conclusion profit transfer agreement significant german corporation include trade corporation tax group parent company c h boehringer sohn ag co kg january income taxis shareholder c h boehringer sohn ag co kg incur operating income report consolidated profit loss statement tax product portfolio expense represent trade income tax affect company apply primarily fully consolidated german partnership total defer tax asset amount eur million balance sheet date previous year mil lion defer tax asset primarily relate difference carry amount recognise provision pension rebate intercompany elimination claim relate loss carry forward tax credit fix asset inventory defer tax liability eur million previous year eur million recognise primarily relate difference carry amount tangible asset inventory provision net income net income positively influence priorperiod operating income essentially reversal provision eur million previous year eur million negatively influence priorperiod operating expense eur million previous year eur million note cash flow statement cash flow statement show change cash cash equivalent cash longterm security investment classify current asset sell time boehringer ingelheim group result cash outflow report year accordance german accounting standard cash flow statement dr cash flow statement break accord cash flow operating activity cash flow invest financing activity change balance sheet item affiliate company include translate average rate year balance sheet cash cash equivalent carry closing rate effect exchange rate change cash cash equivalent show separately financial fund comprise financial asset remain maturity excess month date acquisition financial asset convert cash shortterm financial fund comprise follow item million eur cash cash equivalent security financial asset financial fund include cash equivalent eur million restrict disposal consolidate financial statement note boehringer ingelheim furthermore payment escrow account eur million escrow account include financial fund financial year interest eur million previous year eur million receive eur million previous year eur million interest pay tax payment amount eur million previous year eur million course sale generic business boehringer ingelheim receive share value eur million share show investment relate company yearend disclosure contingent liability millions eur liability guarantee bill cheque guarantee warranty grant security thirdparty liability risk utilisation individual contingent liability estimate follow risk utilisation guarantee liability affiliate company bank rate low account solid net asset financial position result operation subsidiary question financial commitment offbalance sheet transaction millions eur rental leasing obligation purchase commitment obligation rental lease agreement eur million previous year eur million eur million previous year eur million relate longterm rental agreement sub sidiarie include consolidation purpose lease agreement low capital commitment compare buy property absence resale risk risk arise term lease possible continue utilise property fully indication time financial commitment include future expense followup investment investment initiate future major repair balance sheet date purchase commitment include future cash flow effect investment total eur million previous year eur million product portfolio derivative financial instrument valuation unit extensive international structure boehringer ingelheim group highly dependent devel opment world currency interest rate hedge risk particularly emerge good service finance currency forwards option generally currency risk interest rate swap option interest rate risk use derivative financial instrument organisational process set internal guide line strict separation trading processing documentation control risk position regularly track analysed measure special groupwide financial report position enter periodically reevaluate monitor fair market value derivative financial instrument calculate standard market measurement method currency interest forwards net present value method currency interest option recognise option pricing model basis market datum available balance sheet date currency interest option recognise fair market value exceeding option premium pay receive derecognised maturity provision eur million recognise currency forward include hedge accounting negative fair market value currency balance sheet date line imparity principle positive fair market value currency recognise balance sheet date derivative financial instrument include hedge accounting valuation group follow nominal value market value millions eur foreign exchange forward contract extent requirement hedge account foreign currency forward exchange contract highly probable forecast transaction accordance section hgb meet foreign currency forward exchange contract recognise balance sheet line net hedge presentation method follow accounting policy apply recognition hedge accordance section hgb economic hedge account financial statement use valuation group valuation group recognise foreign currency base net highly probable forecast trans action currency forwards match forecast net cash flow term maturity nominal foreign currency macro hedge highly probable forecast transaction income outgoing payment plan sale purchase derive company plan expost analysis planning show plan transaction highly probable consolidated financial statement note boehringer ingelheim oppose change value hedge item hedge instrument fully offset critical term maturity nominal foreign currency match effective hedge assume prospectively retrospectively critical term match method exclusively measure pro spective retrospective effectiveness hedge exceed hedge valuation group december hedge highly probable forecast net cash flow recognise follow january december net cash flow million eur fx forward contract millions eur nominal value nominal value market value usd usd usd jpy jpy jpy aud aud aud mxn mxn mxn cad cad cad gbp gbp gbp january december net cash flow million eur fx forward contract millions eur nominal value nominal value market value usd usd usd jpy jpy jpy aud aud aud mxn mxn mxn cad cad cad gbp gbp gbp january december net cash flow million eur fx forward contract millions eur nominal value nominal value market value usd usd usd jpy jpy jpy january february net cash flow million eur fx forward contract millions eur nominal value nominal value market value jpy jpy jpy product portfolio furthermore december hedge foreign currency receivable recognize follow receivables millions eur forward exchange contract millions eur nominal value nominal value market value rub rub rub pln pln pln hedge foreign currency risk correlate relative change exchange rate planning date realisation date forecast transaction currency appreciate depreciate euro foreign currency risk plus minus eur million hedge loan agreement raise variable interest rate july fully redeem interest rate swap congruent maturity arrange reduce associated risk interest change expire schedule hedge accounting end research development expense millions eur research development expense noncapitalise research development expense include item cost associate phase iv clinical study consolidate financial statement note boehringer ingelheim report postbalance sheet date event boehringer ingelheim sanofi confirm successful completion strategic business swap sanofis animal health business merial boehringer ingelheim consumer health care business chc january signing contract june closing carry plan step represent successful completion business exchange begin exclusive negotia tion december researchbase pharmaceutical company boehringer ingelheim improve future market position field animal health significantly establish future large global player segment bundle merial boehringer ingelheim complementary product portfo lio exist technology platform vaccine antiparasitic pharmaceutical specialty product company place key growth segment industry offer global customer additional add value innovation expect current sale animal health business going double transaction return consumer healt care division give sanofi business unit generate sale eur million boehringer ingelheim corresponding share total turnover group fiscal year end financial year aware event material significance group company lead reappraisal net asset financial position result operation total auditor fee total fee charge group auditor financial year eur million eur million relate audits financial statement eur million assurance service eur mil lion services product portfolio auditor report audit consolidated financial state conduct audit consolidate finan ment prepare ch boehringer sohn ag cial statement accordance article co kg ingelheim comprise balance hgb handelsgesetzbuch german commercial sheet income statement statement change code german generally accept standard equity cash flow statement note audit financial statement promulgate consolidated financial statement institut der wirtschaftsprfer institute group management report business public auditor germany idw stand year january december ards require plan perform audit preparation consolidated financial state misstatement materially affect ment group management report presentation net asset financial position accordance german commercial law result operation consolidated responsibility manage director financial statement accordance german manage corporate general partner responsi principle proper accounting group bility express opinion consolidated management report detect reasonable financial statement group management assurance knowledge business activity report base audit economic legal environment group expectation possible misstate ment take account determination audit procedure effectiveness accountingrelate internal control system evidence support disclosure consoli date financial statement group manage ment report examine primarily test basis framework audit audit include assess annual financial statement company include consolidation determination company include consolidation accounting consolidation principle significant estimate manage director manage corporate general partner evaluate overall presentation consolidate financial state ment group management report believe audit provide reasonable basis opinion consolidated financial statement note boehringer ingelheim exception follow qualification audit lead reservation contrary article nos b hgb total remuneration grant member member board manage direc tor member supervisory body pension provision recognize recognize member board manage director disclose note consolidated financial statement opinion base finding audit qualification mention con solidate financial statement comply legal requirement true fair view net asset financial position result operation group accordance ger man principle proper accounting group management report consistent consoli date financial statement comply legal requirement provide suitable view group position suitably present opportunity risk future development frankfurt main march pricewaterhousecooper gmbh wirtschaftsprfungsgesellschaft dr ulrich strk michael conrad wirtschaftsprfer wirtschaftsprfer german certify german certify public accountant public accountant product portfolio p r u c p r f l e l e c n prescription medicine animal health animal health product overview base portfolio strate gic business swap boehringer ingelheim sanofi finalise boehringer ingelheim consumer healthcare business chc transfer sanofi boehringer ingelheim acquire sanofis animal health business merial merial portfolio reflect overview product portfolio prescription medicine boehringer ingelheim respiratory disease respiratory disease common chronic obstructive bronchial asthma pulmonary disease copd bronchial asthma bronchial asthma chronic inflammatory disorder prevalent chronic disease frequent airways inflammation accompany airway cause morbidity premature death worldwide hyperresponsiveness lead narrow airways recurrent episode wheeze breathless idiopathic pulmonary fibrosis ipf rare disease ness cough symptom occur particularly severely debilitate ultimately lethal night early hour morning know asthma trigger genetic envi copd ronmental factor eg allergen viral infection copd chronic disease lung cause cough unlike copd asthma occur early childhood ing excessive mucus production inflammation present adolescent adult asthma ultimately destroy lung tissue alveolus gas underestimate easytomanage condition exchange affect lead limitation patient asthma airflow cause shortness breath respira experience symptom receive maintenance ther tory symptom airflow limitation partially apy put increase risk potentially reversible usually worsen time lead disa lifethreatening asthma exacerbation bility ultimately death symptom excess cough breathlessness main reason copd stressful patient lung emphysema chronic bronchitis main manifestation copd copd cause continuous damage lung result ing inhale pollutant primarily cigarette smoke factor need consider includ ing indoor outdoor air pollution course copd disease occur second half human life characterise accelerate loss lung function compare normal age occasional sudden worsen symptom f unction refer acute exacerbation lead downward spiral worsen symptom fur ther inactivity indication brand name active ingredient chronic obstructive spiriva tiotropium bromide maintenance treatment patient pulmonary disease copd spiriva handihaler copd include chronic bronchitis spiriva respimat emphysema maintenance treatment associate dyspnoea prevention exacerbation bronchial asthma spiriva respimat tiotropium bromide addon maintenance treatment adult patient asthma currently treat maintenance combination inhale corticosteroid spiriva respimat approve use asthma eu japan usa country label vary country refer local product information chronic obstructive spiolto respimat tiotropium bromide maintenance treatment airflow pulmonary disease copd stiolto respimat olodaterol obstruction patient chronic inspiolto respimat hydrochloride obstructive pulmonary disease copd chronic obstructive striverdi respimat olodaterol maintenance treatment patient pulmonary disease copd hyrochloride chronic obstructive pulmonary disease copd reversible bronchospasm combivent respimat ipratropium bromide combination shortacting associate obstructive salbutamol sulphate anticholinergic betaadrenergic airway disease management reversible broncho spasm associate obstructive airway disease patient require bronchodilator chronic obstructive atrovent ipratropium bromide prevention treatment shortness pulmonary disease copd breath patients chronic chronic bronchitis obstructive pulmonary disease copd bronchial asthma mild moderate bronchial asthma adulthood childhood supple ment betaagonist case acute asthma chronic obstructive airway berodual ipratropium bromide fenoterol prevention treatment symptom disorder bronchodual hydrobromide chronic obstructive airway disorder duovent reversible airflow limitation bronchial asthma especially chronic bronchitis emphysema product portfolio prescription medicine boehringer ingelheim respiratory disease continue idiopathic pulmonary fibrosis ipf acute ipf exacerbation define rapid deterioration ipf progressive lung disease associate markedly symptom lung function day week reduced life span affect people event occur point course disease worldwide ipf characterise progressive presentation associate high mor scar lung tissue loss lung function tality patient ipf risk acute ipf exacer time development scar tissue call fibrosis bation time tissue thickens stiffen scar lung lose ability transfer oxygen blood tream vital organ oxy gen result individual ipf experience shortness breath rest difficulty participate everyday physical activity indication brand name active ingredient bronchial asthma berotec fenoterol hydrobromide symptomatic treatment acute asthma attack prophylaxis exerciseinduce asthma bronchiale symptomatic treatment allergic nonallergic asthma bronchiale condition reversible airway narrow eg chronic obstructive bronchitis bronchial asthma alesion epinastine hydrochloride prophylactic treatment patient allergic rhinitis flurinol bronchial asthma prophylaxis symp tomatic treatment allergic rhinitis idiopathic pulmonary fibrosis ofev nintedanib esylate treatment patient idiopathic ipf pulmonary fibrosis ipf product portfolio prescription medicine boehringer ingelheim cardiovascular metabolic disease cardiovascular cv disease leading cause death prevention treatment venous country increase prevalence thromboembolism currently responsible nearly death venous thromboembolism vte umbrella term worldwide key risk factor develop cardio encompasse deep vein thrombosis dvt pulmonary vascular disease presence diabete people embolism pe dvt process occur diabete time likely develop thrombus blood clot form deep vein commonly cardiovascular disease people diabetes calf leg partially completely blocks result life expectancy year shorter flow blood thrombus grow portion proper control diabete treatable risk factor break away main clot travel circulatory vital prevention cardiovascular event system lung lodge blood clot artery lung call pe vte disor stroke der potentially fatal consequence stroke rapidly develop loss brain function cause reduced blood flow affect brain tis patient undergo orthopaedic surgery considerable sue ischaemia lack blood supply risk develop vte chronic venous insufficiency cause thrombosis embolism bleed andor pulmonary hypertension develop long result affect area brain unable term prevent vte event consequence function damage quickly permanent orthopaedic surgery patient receive kind untreated stroke acute event require emergency thromboprophylaxis patient suffer diagnosis intervention worldwide stroke vte require anticoagulant treatment secondary leading cause death longterm disability prevention recurrent thromboembolic event symptom transient ischaemic attack tia similar stroke minute hour reverse anticoagulation usually result permanent neurological damage anticoagulant offer important benefit patient risk tia precede stroke emergency medical care thromboembolic event rare subsequent preventive treatment necessary situation rapid reversal anticoagu lation medically necessary eg patient take atrial fibrillation anticoagulant involve severe car accident atrial fibrillation af common sustained need emergency surgery heart rhythm condition affect approximately cent total population adult develop arrhythmia lifetime patient af high risk develop blood clot upper leave heart chamber cause disable stroke clot break loose travel brain af lead fivefold increase risk stroke result ing million patient worldwide suffer afrelate stroke year risk stroke reduce effective chronic anticoagulation indication brand name active ingredient stroke prevention atrial pradaxa dabigatran etexilate prevention stroke blood clot fibrillation pradaxar patient abnormal heart rhythm primary prevention venous prazaxa atrial fibrillation thromboembolic event orthopaedic surgery primary prevention venous thrombo treatment secondary embolic event vte adult prevention venous throm elective total hip knee replacement boembolic event surgery treatment deep vein thrombosis dvt pulmonary embolism pe secondary prevention recurrent dvt pe adult specific reversal pradaxa praxbind idarucizumab praxbind specific reversal agent dabigatran etexilate dabigatran indicate adult patient treat pradaxa dab igatran etexilate rapid reversal anticoaculant effect require emergency surgeryurgent procedure lifethreatene uncontrolled bleed hypertension micardis telmisartan treatment hypertension cardiovascular morbidity micardisplus telmisartan hydrochlorothiazide reduction risk myocardial mortality prevention micardi plus infarction heart attack stroke death cardiovascular cv cause micardishct patient year age old high comicardi risk develop major cv event unable ace inhibitor usa reduction cardiovascular morbidity patient manifest atherothrombotic cardiovascular disease history coronary heart disease stroke peripheral arterial disease patient type diabete mellitus document target organ damage eu h ypertension twynsta telmisartan amlodipine treatment hypertension micamlo antihypertensive agent initial micardis amlo therapy patient likely need multi ple antihypertensive agent achieve micardis duo blood pressure goal usa addon therapy adult patient adequately control blood pre sure amlodipine replacement therapy adult patient receive tel misartan amlodipine separate tablet eu product portfolio prescription medicine boehringer ingelheim cardiovascular metabolic disease continue hypertension cardiovascular disease hypertension refer high blood pressure chronic disease blood pressure chronically elevated hypertension major risk factor stroke heart attack heart failure chronic renal failure primary goal antihypertensive treatment prevent cardiovascular event reduce cardiovascular mortality acute myocardial infarction acute myocardial infarction heart attack event occur thrombus clot suddenly pre vent blood flow area heart muscle blood flow restore quickly affect section heart muscle permanently damage heart attack leading cause death develop country indication brand name active ingredient acute ischaemic stroke actilyse alteplase fibrinolytic treatment acute ischae acute myocardial infarction actilyse cathflo mic stroke acute myocardial infarction acute massive pulmonary acute massive pulmonary embolism embolism fibrinolytic treatment occluded catheter clearance catheter thrombotic occlusion secondary prevention aggrenox dipyridamole prevention stroke follow initial stroke transient ischaemic asasantin acetylsalicylic acid stroke transient ischaemic attack tia asasantin retard attack tia acute myocardial infarction metalyse tenecteplase fibrinolytic treatment acute myocar dial infarction hypertension catapresan clonidine treatment hypertension catapre hydrochloride clonidine catapressan cataprestts hypertension motens lacidipine treatment hypertension product portfolio prescription medicine boehringer ingelheim cardiovascular metabolic disease continue diabete approximately cent death people type type diabetes chronic progressive condition associate diabete cause cardiovascular disease indicate elevated blood sugar level cause longterm high unmet medical need complication treat addition cardiovascular disease complication year million death worldwide link directly diabete include nephropathy lead renal failure longterm effect diabete type diabete potentially dialysis retinopathy potential loss common form diabetes account vision peripheral neuropathy risk foot ulcer case develop world affect mil foot leg amputation autonomic neuropathy caus lion people worldwide impose enormous burden e gastrointestinal genitourinary cardiovascular health care system globally effective preven symptom sexual dysfunction tion management strategy estimate number case reach million type diabete major risk factor cardio vascular disease life expectancy people type dia bete high cardiovascular risk average decrease year indication brand name active ingredient type diabete mellitus trajenta linagliptin treatment type diabete mellitus tradjenta improve glycaemic control adult trazenta monotherapy metformin tolerate contraindicated trayenta combination therapy type diabete mellitus jentadueto linagliptin metformin hydrochloride treatment type diabete mellitus trayenta duo improve glycaemic control adult trajenta duo treatment metformin lead sufficient control trajentamet patient treat trajenta linagliptin metformin type diabete mellitus jardiance empagliflozin treatment adult type diabete jardianz mellitus adjunct diet exer cise improve glycemic control reduce risk cardiovascular death patient establish cardiovas cular disease type diabete mellitus synjardy empagliflozin treatment type diabete mellitus metformin improve glycaemic control adult hydrochloride treatment metformin lead sufficient control patient treat jardiance empagliflozin metformin type diabete mellitus glyxambi empagliflozin linagliptin treatment type diabete mellitus improve glycaemic control adult treatment empagliflozin linagliptin appropriate iabete portfolio collaboration eli lilly company product portfolio prescription medicine boehringer ingelheim oncology cancer threat global health estimate disease year appear late diag million new case cancer diagnose world nosis advanced stage disease result wide million people die cancer stewart dismal prognosis lung cancer world cancer report common diagnose patient survive year follow diagnosis cancer type lung cancer nearly breast cancer colorectal cancer approx lung cancer disease dif ferent subtype small cell lung cancer sclc lung cancer nonsmall cell lung cancer nsclc differ lung cancer refer malignant abnormal cell growth ent molecular genetic aberration mutation present inside lung tissue form cluster tumour tumour identify focus molecular common cancer estimate million new change specific respective subtype lung case year worldwide smoking primary cancer target therapy effective cause disease contribute nearly treatment survival benefit case recently incidence lung cancer time harmful normal cell nonsmoker increase lung cancer poor prog reduce effect nosis million death year represent cancer death lung cancer symptom unspecific indication brand name active ingredient nonsmall cell lung cancer giotrif afatinib treatment patient meta nsclc gilotrif static nonsmall cell lung cancer nsclc tumour activate epidermal growth factor receptor egfr mutation treatment patient locally advanced metastatic nsclc squamous histology progress e platinum base chemo therapy nonsmall cell lung cancer vargatef nintedanib combination therapy docetaxel nsclc treatment adult patient locally advanced metastatic locally nonsmall cell lung cancer nsclc adenocarcinoma tumour histology firstline chemotherapy product portfolio prescription medicine boehringer ingelheim disease central nervous system mental neurological disease depression dementia depression sleep disorder primary parkinson disease significantly impact patient symptom result lack neurotransmitter family substantial burden society dopamine distinct area human brain parkinson disease restless leg syndrome rls parkinson disease pd degenerative disorder restless leg syndrome rls common neurological central nervous system patient usually notice motor disorder characterise uncontrollable urge symptom like hand tremor shake sign leg primarily occur evening night disease progress include shake hour usually accompany unpleasant arm leg head motor symptom time painful sensation leg disturb develop time include stiffness result sleep result daytime tiredness sleepiness loss facial expression gradual slow loss sensation feel deep leg describe motion freeze patient suf creep crawl ache f nonmotor symptom associate pd infectious disease hiv infectionaid acquire immune deficiency syndrome aid set symptom infection result damage human immune system cause human immu nodeficiency virus hiv untreated infection hiv progressively reduce effectiveness immune system leave individual susceptible opportunistic infection tumour baby infect mother risk get virus pregnancy childbirth breastfeed indication brand name active ingredient parkinson disease pd sifrol pramipexole symptomatic treatment idiopathic restless leg syndrome rls mirapex parkinson disease mirapexin monotherapy combination levodopa symptomatic treatment pexola idiopathic moderate severe restless leg syndrome sleep disorder lendormin brotizolam shortterm treatment disorder initiate maintain sleep insomnia require pharmacological intervention indication brand name active ingredient hivaid viramune nevirapine combination therapy hiv viramune xr infection country prevention mothertochild trans mission hiv pregnant woman take antiretroviral therapy time labour prolong release tablet oncedaily dose combination therapy hivaids aptivus tipranavir indicate combination antiretroviral treatment hivinfecte patient coadministere mg ritona vir treatmentexperience infect hiv strain resistant protease inhibitor product portfolio animal health boehringer ingelheim reference animal health product overview base port chc transfer sanofi boehringer ingelheim folio strategic business acquire sanofis animal health business merial swap boehringer ingelheim sanofi final merial portfolio reflect overview ise boehringer ingelheim consumer healthcare business livestock swine infectious respiratory disease infectious enteric disease ingelvac circoflex singledose piglet vaccine enterisol ileitis vaccine control porcine circovirus disease pcvd ileitis cause lawsonia intracellularis licensed vaccine provide significant reduction mortality improve weight gain reduce growth variability acute phase pcvd improve growth rate associate disease enterisol ileitis help chronic phase disease ingelvac circoflex reduce total antimicrobial use pork production protect minimal systemic adverse reaction injec tion site swelling pregnancy lactation ingelvac prrs product license active immunisation respiratory reproductive form porcine reproductive respiratory syndrome prrs ingelvac mycoflex license active immunisa tion pig enzootic pneumonia ep single dose regimen advance adjuvant system provide longlaste effective protection prove highchallenge situation livestock poultry volvac umbrella brand boehringer ingelheim viral bacterial disease like avian influenza animal health poultry vaccine range consist wide infectious bronchitis newcastle disease infectious bursal range live inactivate vaccine broiler lie disease egg drop syndrome avian coryza ers vaccine provide protection bird indication brand name active ingredient infectious respiratory ingelvac circoflex recombinant vaccine active immunisation pig isease porcine circovirus age week porcine type pcv circovirus type reduce mortality clinical sign include weight loss lesion lymphoid tissue asso ciate porcine circovirus disease pcvd addition vaccination show reduce pcv nasal shed de viral load blood lymphoid tissue duration viraemia infectious respiratory ingelvac prrs mlv attenuate live vaccine prrs virus depend product active isease ingelvac prrsflex eu type prrs mlv immunisation pig age reprocyc type prrsflex eu porcine reproductive reprocyc respiratory syndrome virus prrsv infectious respiratory ingelvac mycoflex inactivate vaccine active immunisation pig isease mycoplasma age week reduce lung hyopneumoniae lesion follow infection myco plasma hyopneumoniae infectious enteric disease enterisol ileitis attenuate live vaccine lawsonia active immunisation pig intracellularis age week intestinal lesion cause lawsonia intracellula ris infection reduce growth varia bility loss weight gain associate disease indication brand name active ingredient viral bacterial volvac polyvalent attenuate live vaccination healthy chicken disease poultry inactivated vaccine disease cause contain antigen include antigen prevention vaccination avian common disease broiler influenza newcastle chicken disease responsible disease avian coryza egg loss egg production layer drop syndrome infectious bronchitis infectious bursal disease bacterium anatis product portfolio animal health boehringer ingelheim livestock cattle mastitis mastitis inflammation udder dairy cattle mainly cause bacterial infection prevention treatment mastitis animal key produce healthy milk minimise symptom associate clinical situation mamyzin effective injectable antimicrobial treatment acute masti tis ubrolexin today product treatment acute bacterial mastitis ubrostar tomorrow prevent mastitis dry ingoff dairy cattle end lactation period indication brand name active ingredient astitis mamyzin penethamate hydroiodide bovine mastitis cause penicillin sensitive organism astitis ubrostar penethamate hydroiodide framyce treatment subclinical mastitis benestermycin tin sulphate benethamine penicillin dryingoff prevention new mamyzin secado bacterial infection udder dry period dairy cow cause bacteria susceptible penicillin framycetin astitis ubrolexin cefalexin kanamycin combination treatment clinical mastitis lactate dairy cow bacteria susceptible combination cefalexin kana mycin astitis today cephapirin sodium treatment clinical mastitis lactate cefalak dairy cow uscanada astitis tomorrow cephapirin benzathine treatment subclinical mastitis cefadri dryingoff prevention new bacterial infection udder dry period dairy cow uscan ada intramammary infusion dry cow product portfolio animal health boehringer ingelheim livestock cattle continue pain inflammatory disorder infectious disease metacam nonsteroidal antiinflammatory drug pyramid family vaccine provide broad nsaid address need maintain profita coverage respiratory reproductive disease bility concern animal welfare animal pro range consist antigen combination duction longacte nature outstand ing efficacy control inflammatory symptom bovine viral diarrhoea virus bvdv major metacam help minimise loss inflammation economically relevant cattle pathogen maintain profitability time metacam worldwide distribution disease cause bvdv effectively control pain support restoration result mark production loss dairy beef wellbee farm animal use metacam herds bovela vaccine design reduce convenient inflict minimal stress animal clinical sign typical bvd prevent lowvolume oneshot dosage birth socalle persistently infect animal cause transplacental infection bvdv vaccina metacam license adjunctive therapy treat tion bovela expect provide protection ment mastitis lactate cow country herd disease cir indicate use calf affect diarrhoea culation virus cattle suffer respiratory disease indication brand name active ingredient pain inflammatory metacam meloxicam cattle metacam isorder appropriate antibiotic therapy reduce clinical sign disease acute respiratory infection diarrhoea combination oral rehydration therapy reduce clinical sign disease calf week age young nonlactate cattle relief postoperative pain follow dehorn calf supportive therapy treatment acute mastitis com bination antibiotic cattle infectious disease pyramid multivalent vaccine combina vaccination healthy dairy beef respiratory reproductive presponse tion include modify live virus cattle aid prevention disease disease cattle bovine viral diarrhoea bvd type cause include antigen infectious bovine rhinotrache canada itis ibr parainfluenza pi bovine respiratory syncytial virus brsv bacteria pasteurella multocida mannheimia haemolyt ica l canicola l grippotyphosa l hardjo l icterohaemmorrhagiae l pomona bovine viral diarrhoea bvd bovela modify live bvdv strain bovela protect cattle modify live bvdv strain bvd viral infection bovine viral diarrhoea virus product portfolio animal health boehringer ingelheim companion animal horse main horse product focus therapeutic area vetera vaccine formulate utilise ultrafil respiratory disease lameness colic hormonal dis purification technology remove extraneous pro order tein allow horse immune system focus relevant antigen prascend indicate treatment pituitary par intermedia dysfunction ppid know respiratory segment product available global equine cushing disease prascend substitute level ventipulmin equisolon product lack dopamine pituitary par intermedia clinical license treatment respiratory disease include airway sign hypertrichiosis laminitis change body con obstruction horse wheeze cough difficulty formation lack performance treatment pras breathe bronchospasm andor mucus accumulation cend lifelong ventipulmin equisolon adjunctive therapy chronic obstructive pulmonary disease vetera vaccine vaccine portfolio copd acute subacute chronic respiratory allergic include multiple convenient combination disease pro condition tection horse young month age vaccine protect infectious organism include influenza herpe west nile virus tetanus enable customised protec tion horse limited needle injection indication brand name active ingredient pituitary par intermedia prascend pergolide mesylate symptomatic treatment clinical sign dysfunction ppid associate pituitary par intermedia dysfunction ppid know equine cushing disease combination vaccine vetera eastern western venezuelan vaccination healthy horse common disease encephalomyelitis tetanus west aid prevention disease cause horse nile virus equine include antigen herpe virus equine ada influenza viruse acute chronic obstructive ventipulmin clenbuterol treatment respiratory disease horse respiratory disease airway obstruction bron chospasm andor accumulation mucus improve mucociliary clear ance desirable recurrent airway obstruction equisolon prednisolone treatment recurrent airway rao heave obstruction rao heave horse combination environmental measure product portfolio animal health boehringer ingelheim companion animal small animal main small animal product address major chronic prozinc aqueous protamine zinc pzi suspension disease heart failure kidney disease epilepsy recombinant human insulin reduce osteoarthritis hyperglycaemia cat diabetes mellitus new class heart treatment term semintra angiotensin ii antagonist inodilator vetmedin show significantly approve reduction proteinuria associate improve clinical sign extend life expectancy dog chronic kidney disease ckd cat semintra congestive heart failure originate dilate decrease mean arterial blood pressure proteinuria cardiomyopathy valvular insufficiency mitral andor available oral solution tricuspid regurgitation vetmedin work complementary mode action open blood pexion alternative treatment canine epilepsy vessel take blood away heart active substance imepitoin primarily inhibit sei lower pressure heart reduce zure potentiation gabaareceptormediate work heart pump blood dog inhibitory effect neuron pexion approve body time vetmedin direct effect reduction generalise seizure idiopathic epi heart muscle helping beat strong pump lepsy potential safety benefit exist blood efficiently standard treatment metacam nonsteroidal antiinflammatory drug nsaid available oral suspension tablet injectable solution dog oral suspen sion injectable solution cat dog indica tion include alleviation inflammation pain acute chronic musculoskeletal disorder reduction pain follow surgery cat indication include alleviation inflammation pain acute chronic musculoskeletal disor der alleviation mild moderate post operative pain variety formulation offer veteri narian owner flexibility use formulation prefer individual case manage level inflammation pain associate license indication indication brand name active ingredient congestive heart failure vetmedin pimobendan treatment canine congestive heart failure originate dilatative cardio myopathy valvular insufficiency mitral andor tricuspid regurgitation treatment dilate cardiomyopa thy preclinical stage asymptomatic increase leave ventricular endsystolic enddiastolic diameter doberman pinscher follow echo cardiographic diagnosis cardiac disease pain inflammatory metacam meloxicam dog metacam reduce disease postoperative pain inflammation follow orthopaedic eg fracture oper ation soft tissue surgery cat metacam reduce postoperative pain inflammation ovariohysterectomy spay opera tion orthopaedic minor soft tissue surgery alleviation pain inflammation acute chronic musculoskeletal disorder dog cat feline diabete mellitus prozinc protamine zinc reduction hyperglycaemia recombinant hyperglycaemiaassociated clinical sign human insulin cat diabete mellitus feline chronic kidney disease semintra telmisartan reduction proteinuria associated chronic kidney disease ckd cat canine idiopathic epilepsy pexion imepitoin reduction frequency generalise seizure idiopathic epilepsy dog careful evaluation alternative treatment option comparison balance sheet boehringer ingelheim c h boehringer sohn ag co kg ingelheim comparison balance sheet million eur asset december intangible asset tangible asset financial asset fix asset inventory account receivable incl defer charge defer taxis liquid fund current asset incl defer charge defer taxis total asset liability equity december shareholder capital group reserve incl currency conversion difference group profit equity attributable parent company noncontrolle interest group equity difference capital consolidation provision incl defer taxis liability incl defer charge total liability incl defer taxis defer charge total liability equity summary select financial datum net sale operating income operating income net sale income taxis income taxis net sale return equity equity ratio cash flow financial fund personnel expense personnel expense net sale average number employee research development cost rd net sale investment tangible asset depreciation tangible asset imprint asset december intangible asset tangible asset financial asset boehringer ingelheim gmbh binger strae fix asset ingelheim inventory germany account receivable incl defer charge defer taxis telephone fax liquid fund current asset incl defer charge defer taxis contact total asset corporate division communication public affair email pressboehringeringelheimcom internet wwwboehringeringelheimcom liabilitie equity december shareholder capital issue group reserve incl currency conversion difference boehringer ingelheim gmbh group profit concept design layout equity attributable parent company mpm corporate communication solution mainz noncontrolle interest wwwmpmde group equity difference capital consolidation photo provision incl defer taxis dieth schrder fotografie p liabilities incl defer charge print total liability incl defer taxis defer charge neue sddeutsche verlagsdruckerei gmbh ulm total liability equity copyright boehringer ingelheim gmbh summary select financial datum right reserve annual report net sale reproduce transmit form mean operate income electronic photocopy permission write boehringer ingelheim gmbh figure party operating income net sale annual report base datum available time income taxis financial statement draw income taxis net sale return equity equity ratio cash flow financial fund personnel expense personnel expense net sale average number employee research development cost rd net sale investment tangible asset depreciation tangible asset wwwboehringeringelheimcom annualreportboehringeringelheimcom